Today, JAMA published Toward a Healthier Future Through Obesity Prevention and Care: The #jamasummit Report on Obesity.
🔗 Read the full report: jamanetwork.com/journals/jama/fullarticle/2856764?linkId=…
#obesityweek #ow2026
JAMA Oncology
JAMA Oncology is a monthly peer-reviewed medical journal published by the American Medical Association. It covers all aspects of medical oncology, radiation oncology, and surgical oncology, as well as subspecialties. The journal was established in 2015. The founding editor-in-chief is Mary L. Disis. More on Wikipedia
-
JAMA Oncology
@JAMAOnc
-
JAMA Oncology
@JAMAOnc
Join JAMA and JAMA Network Editor in Chief Kirsten Bibbins-Domingo, PhD, MD, MAS, and leading experts in #obesity research, treatment, and policy for an inside look at Toward a Healthier Future: The #jamasummit Report on Obesity.
➡️ Register now: jamanetwork.com/pages/jama-summit-obesity?linkId=1038967281 -
JAMA Oncology
@JAMAOnc
For patients with resectable locally advanced #headandnecksquamouscellcarcinoma, perioperative camrelizumab plus chemotherapy improved 2-year event-free survival vs standard surgery-based treatment. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
For patients with #nasopharyngealcarcinoma receiving chemoradiotherapy, early oral nutritional supplementation reduced significant weight loss and severe radiation-induced oral mucositis compared with routine supplementation
jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… -
JAMA Oncology
@JAMAOnc
In ERBB2-positive metastatic #breastcancer, first-line treatment is shifting beyond taxane-based induction toward newer regimens and expanded maintenance options that may change treatment sequencing and duration. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Among trainees providing #cancercare, representation of physicians from groups underrepresented in medicine increased after 2020, but still did not match the diversity of the general US population in 2025. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
In 2027, JAMA will convene leaders across #medicine, research, #technology, industry, and #policy to address how #ai will reshape health care and biomedical science.
Learn more: jamanetwork.com/pages/jama-summit-health-after-ai?linkId=…
#healthafterai #jamasummit -
JAMA Oncology
@JAMAOnc
📝 JAMA Oncology Patient Page: Supplements and Wellness Products During #cancer Care This Patient Page discusses safety when taking supplements and wellness products during cancer treatment. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
A 79-year-old woman with high-risk myelodysplastic syndrome treated with 5-azacitidine presented with painful ulcers on the tongue and right lower extremity. What is your diagnosis? jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
📑 This JAMA Oncology review discusses #chemotherapy decision-making support tools and updated evidence guiding therapeutic decision-making among older adults with early-stage #breastcancer. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
📣 JAMA and the JAMA Network journals are issuing a call for papers on Women's Health.
➡️ Manuscripts submitted by November 15, 2026, will have the best chance for consideration for simultaneous publication on International Women’s Day.
🔗 Learn more: jamanetwork.com/journals/jama/fullarticle/2855130?guestAc… -
JAMA Oncology
@JAMAOnc
In US #cancer clinical trials, industry sponsors were more likely to focus on single-agent drug therapies, while federal sponsors were more likely to evaluate prevention and supportive care interventions. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Presented at #esmo26 from @JAMA_current:
In low erythroblastic oncogene B 2 (ERBB2) advanced #breastcancer, trastuzumab rezetecan showed benefit in hormone receptor–positive and hormone receptor-negative disease.
jamanetwork.com/journals/jama/fullarticle/2855790?guestAc… -
JAMA Oncology
@JAMAOnc
Presented at #esmo26 from @JAMA_current: For low erythroblastic oncogene B 2 (ERBB2) advanced #breastcancer, trastuzumab rezetecan improved progression-free survival vs chemotherapy in both chemotherapy-naive patients and the overall population.
jamanetwork.com/journals/jama/fullarticle/2855791?guestAc… -
JAMA Oncology
@JAMAOnc
In Denmark, #meningioma incidence increased from 2010 to 2023, but #surgery and #radiotherapy rates remained stable, indicating that more diagnoses did not lead to more treatment. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Among patients with early #triplenegativebreastcancer, tissue-free #ctdna detection during molecular residual disease surveillance was strongly prognostic for recurrence and supported testing when tumor tissue was unavailable. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
In patients with #prostatecancer receiving #adaptivetherapy, mathematical biomarkers from first-cycle prostate-specific antigen (#psa) dynamics predicted time to progression and overall survival better than standard PSA metrics. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
#colorectalcancer mortality declined nationally among US adults aged ≥45 years from 2000 to 2019, but county-level disparities persisted, with some counties exceeding 100 deaths per 100 000 among American Indian or Alaska Native and Black populations. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
In #cancercare, biosimilar entry for bevacizumab, rituximab, and trastuzumab was associated with lower reference product prices and market share, along with lower payer and patient costs. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Among men with #prostatecancer starting concurrent androgen deprivation therapy and an androgen receptor pathway inhibitor, #metabolicsyndrome and related abnormalities were frequently documented early, with hypertension the most common outcome. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Among patients with metastatic #breastcancer, alert-based digital patient-reported outcome monitoring was associated with lower fatigue at 6 months vs usual care, with improvement exceeding the minimal clinically important difference.
jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… -
JAMA Oncology
@JAMAOnc
For patients with #renalcellcarcinoma and #inferiorvenacava tumor thrombus, neoadjuvant #stereotacticablativeradiotherapy before surgery appeared feasible, with no 90-day mortality or grade 4-5 radiation toxicities.
jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… -
JAMA Oncology
@JAMAOnc
For localized deficient mismatch repair or microsatellite instability–high #gastriccancer and gastroesophageal junction adenocarcinoma, neoadjuvant nivolumab plus ipilimumab followed by adjuvant nivolumab was associated with sustained long-term survival.
jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… -
JAMA Oncology reposted
JAMA
@JAMA_current
The JAMA Network announces @JAMA_AI_, a new peer-reviewed online journal dedicated to the science of artificial intelligence, digital health, and emerging technologies that are transforming medicine and health care.
Led by inaugural Editor in Chief Roy H. Perlis, MD, MSc, JAMA AI will publish research spanning the full spectrum of AI in health care, from advances in AI capabilities and clinical applications to rigorous evaluation and real-world implementation.
The journal will begin accepting submissions in early 2027.
➡️ Learn more and sign up for updates: jama-ai.com?linkId=1021777473 -
JAMA Oncology
@JAMAOnc
💬 Viewpoint: Response Evaluation Criteria in Solid Tumors remains useful for standardization, but tumor size alone may not reflect treatment benefit in immunotherapy, precision oncology, and molecular monitoring.
jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… -
JAMA Oncology
@JAMAOnc
Among patients with transurethrally unresectable, ERBB2-positive #bladdercancer, disitamab vedotin plus tislelizumab was associated with high complete response and durable disease control, with no muscle-invasive or metastatic progression during follow-up. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
💬 Viewpoint: Response Evaluation Criteria in Solid Tumors remains useful for standardization, but tumor size alone may not reflect treatment benefit in immunotherapy, precision oncology, and molecular monitoring.
jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… -
JAMA Oncology
@JAMAOnc
Among patients with transurethrally unresectable, ERBB2-positive #bladdercancer, disitamab vedotin plus tislelizumab was associated with high complete response and disease control, with no muscle-invasive or metastatic progression during follow-up.
jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… -
JAMA Oncology
@JAMAOnc
💬 Viewpoint: Response Evaluation Criteria in Solid Tumors remains useful for standardization, but tumor size alone may not reflect treatment benefit in immunotherapy, precision oncology, and molecular monitoring.
jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… -
JAMA Oncology
@JAMAOnc
Among patients with transurethrally unresectable, ERBB2-positive #bladdercancer, disitamab vedotin plus tislelizumab was associated with high complete response and durable disease control, with no muscle-invasive or metastatic progression during follow-up. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology reposted
JAMA
@JAMA_current
📣 @JAMA_current and the @JAMANetwork journals are issuing a call for papers on Women's Health.
Last year, we launched @JAMAWomenHealth, an initiative that offers expertly curated research and insights from work published in JAMA and the JAMA Network. An important goal of JAMA+ Women's Health is to shift the conversation about women’s health beyond the “usual” categories of #reproductive #health, #pregnancy, #menopause, and certain #cancers.
To align with the 2027 International Women’s Day, JAMA and the JAMA Network journals will publish women’s health articles across the full spectrum of health care on March 8, 2027.
This call for papers will prioritize timely and novel research articles and opinion manuscripts. Manuscripts submitted by November 15, 2026, will have the best chance for consideration for simultaneous publication on International Women’s Day.
🔗 Click on the link to read the full editorial: jamanetwork.com/journals/jama/fullarticle/10.1001/jama.20… -
JAMA Oncology reposted
Lurie Cancer Center
@LurieCancer
A statement published in @JAMAOnc updates recommendations for the diagnosis, treatment and follow-up of primary localized #chordoma.
Developed by a multidisciplinary panel of experts, including Jean-Paul Wolinsky, MD of @NeurosurgeryNM, it emphasizes personalized care and shared decision-making.
Read the guidance: breakthroughsforphysicians.nm.org/neurosciences-clinical-… -
JAMA Oncology reposted
Jonathan Evan Shoag 🇮🇱🇺🇸
@jeshoag
Our latest in @JAMAOnc prebiopsy MRI is now used in ~2/3 of US prostate biopsies.
Up sharply since 2017 but still work to do.
With Stephen Rhodes and coauthors @SBasourakos @jimhumd @Chris_Barbieri1 @angela_jia_ @Soum_Roy_RadOnc @DrSpratticus @lponsky
@CaseUrology @UHhospitals @UH_RE_Institute @caseccc
jamanetwork.com/journals/jamaoncology/fullarticle/2854308 -
JAMA Oncology reposted
ilyas sahin, MD
@ilyassahinMD
A new @JAMAOnc meta-analysis suggests immunotherapy may worsen outcomes in PD-L1 negative head and neck cancer (SCC) (CPS <1).
Across 7 phase 3 trials, recurrent/metastatic patients had worse survival with immunotherapy than with standard therapy (HR 1.46).
Pooled subgroup data, but a meaningful signal: biomarkers matter. Immunotherapy has transformed cancer care. That doesn’t mean it helps everyone. -
JAMA Oncology reposted
AMA Ed Hub™
@AMAEdHub
How would you diagnose this case? A 58-year-old woman with metastatic breast cancer presented with hypotension, hypoxia, polyuria and polydipsia. MRI revealed multiple enhancing and cystic/necrotic hemorrhagic metastases. What's your diagnosis? @JAMAOnc edhub.ama-assn.org/jn-learning/module/2850489
-
JAMA Oncology reposted
Vivek Subbiah, MD
@VivekSubbiah
⭐️Delivering Precision Oncology at Scale-Infrastructure, Evidence, and the Path Forward @JAMAOnc @OncoAlert @oncodaily jamanetwork.com/journals/jamaoncology/fullarticle/2845810
-
JAMA Oncology reposted
Kristina Jankovic, MD
@JankovicK
Phase III in early #erbb2+ #breastcancer: neoadjuvant anbenitamab, a biparatopic anti-HER2 mAb, + HB1801 (albumin-bound docetaxel) improved tpCR vs THP (both ± carboplatin):
📊 tpCR 62.4% vs 51.2% (P=.004),
Similar grade 3–4 TRAEs
👉 jamanetwork.com/journals/jamaoncology/fullarticle/2853843
@OncoAlert @JAMAOnc -
JAMA Oncology reposted
Kazinform
@kazinform_eng
Differences in smoking, alcohol use and other health factors may account for much of the higher #cancer incidence seen among #men in #china, while explaining far less of the gap in the #uk, according to a study published in JAMA Oncology.
qazinform.com/news/study-reveals-why-cancer-rates-are-hig…
@JAMAOnc -
JAMA Oncology
@JAMAOnc
Among patients with #hepatocellularcarcinoma who underwent #livertransplant, an immune checkpoint inhibitor–based pretransplant strategy was associated with better survival and lower recurrence vs therapy without immune checkpoint inhibitors.
jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… -
JAMA Oncology
@JAMAOnc
In advanced high-grade serous #ovariancancer, early assessment of chemosensitivity may help identify patients most likely to benefit from response-adapted treatment intensification before maintenance therapy. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Among patients with nonmetastatic #headneckcancer receiving radiation therapy, financial toxicity was associated with worse quality of life and substantial out-of-pocket expenses.
jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… -
JAMA Oncology
@JAMAOnc
This JAMA Oncology Review examines ovarian metastases from #colorectralcancer and the potential role of surgical resection of metastatic disease.
jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… -
JAMA Oncology
@JAMAOnc
Among adults in China and the UK, modifiable lifestyle factors and health conditions accounted for most of the male-female #cancer incidence gap in China but only a smaller fraction in the UK.
jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… -
JAMA Oncology
@JAMAOnc
Among adults in China and the UK, modifiable lifestyle factors and health conditions accounted for most of the male-female #cancer incidence gap in China but only a smaller fraction in the UK.
jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… -
JAMA Oncology
@JAMAOnc
Prebiopsy #mri use before #prostatecancer biopsy increased in the US from 2017 to 2026, reaching 64.1% of biopsy-naive patients, but uptake remained incomplete. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
💬Editorial: In HPV 16–positive recurrent or metastatic #headandneckcancer, PDS0101 plus pembrolizumab demonstrated activity in immune checkpoint inhibitor–naive disease but not after prior immune checkpoint inhibitor exposure. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Meta-analysis: Among #headandneckcancer patients with PD-L1 CPS <1, #immunecheckpointinhibitors were linked to poorer survival outcomes, including significantly reduced overall survival in recurrent/metastatic disease. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
In #hpv16-positive recurrent or metastatic #headandneckcancer, PDS0101 plus #pembrolizumab showed antitumor activity and manageable safety in immune checkpoint inhibitor–naive patients, but no objective responses in resistant patients. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
In persistent, recurrent, or metastatic #cervicalcancer, first-line #pembrolizumab plus chemotherapy with or without bevacizumab maintained overall survival and progression-free survival benefit at 5 years, with no new safety signals observed. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
A 76-year-old man presented to the emergency department with 5 days of worsening dyspnea at rest, lower extremity edema, fatigue, confusion, and poor oral intake. What is your diagnosis? jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Among children with relapsed or refractory #bcellacutelymphoblasticleukemia, bicistronic CD19/CD22 #cartcell therapy was associated with high rates of minimal residual disease–negative remission and durable event-free survival. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Among patients with #erbb2-positive #breastcancer, neoadjuvant anbenitamab plus HB1801 was associated with a higher total pathologic complete response rate vs trastuzumab, pertuzumab, and docetaxel, with similar grade 3 or 4 toxic effects.
jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… -
JAMA Oncology
@JAMAOnc
💬 Editorial: In pediatric #acutelymphoblasticleukemia, bicistronic CD19/CD22 #cartcell therapy was associated with durable remission despite limited persistence, challenging the view that prolonged CAR T-cell surveillance is always required. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
📝 JAMA Oncology Patient Page: Supplements and Wellness Products During #cancer Care This Patient Page discusses safety when taking supplements and wellness products during cancer treatment. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
📑 This JAMA Oncology review discusses #chemotherapy decision-making support tools and updated evidence guiding therapeutic decision-making among older adults with early-stage #breastcancer. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
In #cancercare, biosimilar entry for bevacizumab, rituximab, and trastuzumab was associated with lower reference product prices and market share, along with lower payer and patient costs.
jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… -
JAMA Oncology
@JAMAOnc
#colorectalcancer mortality declined nationally among US adults aged ≥45 years from 2000 to 2019, but county-level disparities persisted, with some counties exceeding 100 deaths per 100 000 among American Indian or Alaska Native and Black populations.
jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… -
JAMA Oncology
@JAMAOnc
In US #cancer clinical trials, industry sponsors were more likely to focus on single-agent drug therapies, while federal sponsors were more likely to evaluate prevention and supportive care interventions.
jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… -
JAMA Oncology
@JAMAOnc
In Denmark, #meningioma incidence increased from 2010 to 2023, but #surgery and #radiotherapy rates remained stable, indicating that more diagnoses did not lead to more treatment.
jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… -
JAMA Oncology
@JAMAOnc
A 79-year-old woman with high-risk myelodysplastic syndrome treated with 5-azacitidine presented with painful ulcers on the tongue and right lower extremity.
What is your diagnosis? jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… -
JAMA Oncology
@JAMAOnc
Among patients with early #triplenegativebreastcancer, tissue-free #ctdna detection during molecular residual disease surveillance was strongly prognostic for recurrence and supported testing when tumor tissue was unavailable. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Among men with #prostatecancer starting concurrent androgen deprivation therapy and an androgen receptor pathway inhibitor, #metabolicsyndrome and related abnormalities were frequently documented early, with hypertension the most common outcome. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Among patients with metastatic #breastcancer, alert-based digital patient-reported outcome monitoring was associated with lower fatigue at 6 months vs usual care, with improvement exceeding the minimal clinically important difference.
jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… -
JAMA Oncology
@JAMAOnc
Patients with #cancer aged 15 to 39 who received medical assistance in dying experienced escalating symptoms and often received palliative care later in the disease course compared to the general cancer population.
jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… -
JAMA Oncology
@JAMAOnc
A single-fraction 19 Gy SBRT regimen for localized #prostatecancer achieved 92.9% 3-year biochemical relapse-free survival, with grade 2 genitourinary and gastrointestinal adverse event rates below 10% and 5%, respectively, at 3 years.
jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… -
JAMA Oncology
@JAMAOnc
Adding consolidative thoracic radiotherapy to atezolizumab maintenance for extensive-stage small cell lung cancer led to more severe toxic effects, mainly infections, without survival benefit compared to atezolizumab alone.
jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… -
JAMA Oncology
@JAMAOnc
Adding consolidative thoracic radiotherapy to atezolizumab maintenance for extensive-stage small cell lung cancer led to more severe toxic effects, mainly infections, without survival benefit compared to atezolizumab alone.
jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… -
JAMA Oncology
@JAMAOnc
In patients with #prostatecancer receiving #adaptivetherapy, mathematical biomarkers from first-cycle prostate-specific antigen (#psa) dynamics predicted time to progression and overall survival better than standard PSA metrics.
jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… -
JAMA Oncology
@JAMAOnc
Among patients with metastatic #breastcancer, alert-based digital patient-reported outcome monitoring was associated with lower fatigue at 6 months vs usual care, with improvement exceeding the minimal clinically important difference.
jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… -
JAMA Oncology
@JAMAOnc
Among patients with metastatic #breastcancer, alert-based digital patient-reported outcome monitoring was associated with lower fatigue at 6 months vs usual care, with improvement exceeding the minimal clinically important difference.
jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… -
JAMA Oncology
@JAMAOnc
In patients with #prostatecancer receiving #adaptivetherapy, mathematical biomarkers from first-cycle prostate-specific antigen (#psa) dynamics predicted time to progression and overall survival better than standard PSA metrics.
jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… -
JAMA Oncology
@JAMAOnc
💬 Editorial: The TORCH trial confirms that sequential TACE and thermal ablation improved survival vs TACE alone for intermediate-stage #hcc, with the greatest benefit for low to moderate tumor burden.
jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… -
JAMA Oncology
@JAMAOnc
Dual PD-1/LAG-3 inhibition added to neoadjuvant chemotherapy improved pathologic complete response rates in high-risk ERBB2-negative #breastcancer, with greatest benefit in ImPrint biomarker–positive patients.
jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… -
JAMA Oncology
@JAMAOnc
A phase 3 trial found that sequential transarterial chemoembolization followed by thermal ablation significantly improved progression-free and overall survival vs TACE alone for unresectable, liver-confined #hcc.
jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… -
JAMA Oncology
@JAMAOnc
Receipt of prostate-specific membrane antigen positron emission tomography for #prostatecancer staging was associated with higher initiation rates of androgen receptor pathway inhibitor therapy and increased use of systemic treatment. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
This Review examines the clinical utility of circulating tumor DNA assays for detecting minimal residual disease in patients with early-stage #breastcancer.
jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… -
JAMA Oncology
@JAMAOnc
Relabeling grade group 1 #prostatecancer as precancerous was predicted to decrease US mortality, with six times more deaths avoided through increased screening than caused by reduced surveillance adherence. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Adding consolidative thoracic radiotherapy to atezolizumab maintenance for extensive-stage small cell lung cancer led to more severe toxic effects, mainly infections, without survival benefit compared to atezolizumab alone.
jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… -
JAMA Oncology
@JAMAOnc
💬 Viewpoint: In #oncology, payment incentives may shape the context of care recommendations, and directional disclosure of those incentives deserves consideration as part of informed consent.
jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… -
JAMA Oncology
@JAMAOnc
In a phase 1 trial of ultralow-dose IL-10–expressing CD19 CAR T cells for diffuse large B-cell lymphoma, 92% of adults had objective responses and most toxicities were grade 1-2, supporting further evaluation of cytokine-engineered CAR T strategies.
jamanetwork.com/journals/jamaoncology/fullarticle/2851990… -
JAMA Oncology
@JAMAOnc
Early-stage #lungcancer diagnoses increased nationally and in all states after screening recommendations in 2013, but fewer than 1 in 5 eligible adults are up to date with screening. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
A meta-analysis found first-line chemoimmunotherapy provided longer overall and progression-free survival than PD-(L)1 inhibitor monotherapy in advanced #nsclc with high #pdl1, though with greater toxicity. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Study of veterans with cancer identified high rates of suicidal self-directed violence, with greatest risk in younger, female, American Indian or Alaska Native, and those with central nervous system, pancreas, liver, thyroid, or head and neck cancer. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Adding intraperitoneal paclitaxel to intravenous paclitaxel plus S-1 improved overall survival for #gastriccancer with peritoneal metastasis, with safety profiles comparable to intravenous-only therapy. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Among patients with early age–onset #colorectalcancer in Texas, treatment delays longer than six weeks were associated with reduced survival, and language barriers represented a major risk factor contributing to delayed initiation of definitive therapy. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
High modifiable risk factors were more strongly associated with #pancreaticcancer for adults aged <60 years, especially those with high genetic risk, supporting early-life prevention strategies. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Nearly half of older adults with metastatic #lungcancer did not receive systemic therapy, and treatment rates changed minimally from 2006 to 2021. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Tumor-infiltrating clonal hematopoiesis was detected in 18% of patients with solid tumors and associated with older age, prior cytotoxic chemotherapy, and reduced overall survival, especially in breast cancer. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
A 56-year-old man had a 10year history of recurrent, generalized violaceous papules and firm nodules. What is your diagnosis? ➡️ Take the JAMA Oncology Clinical Challenge: jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Between 1991-1995 and 2019-2023, reduced lung, prostate, and esophageal cancer mortality in Black males and colorectal, cervical, and lung cancer in Black females contributed most to narrowing the Black-White cancer mortality gap. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
In metastatic breast cancer trials, progression-free survival by blinded central review and investigator assessment was similar, supporting use of either method for endpoint evaluation.
jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… -
JAMA Oncology
@JAMAOnc
Presented today at #isth2026 from @JAMA_current:
Among patients with #cancer and suspected #pe, use of the YEARS algorithm safely reduced CT #pulmonary #angiography, with 22% avoiding imaging and similar 90-day VTE rates to CTPA-only care.
🔗 jamanetwork.com/journals/jama/fullarticle/10.1001/jama.20… -
JAMA Oncology
@JAMAOnc
This Special Communication updates and expands the 2015 consensus recommendations on the diagnosis, treatment, and follow-up of pediatric and adult patients with primary, localized chordoma. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Adding consolidative thoracic radiotherapy to atezolizumab maintenance for extensive-stage small cell lung cancer led to more severe toxic effects, mainly infections, without survival benefit compared to atezolizumab alone. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Among patients with advanced #biliarytractcancer, durvalumab plus gemcitabine and cisplatin provided sustained 4-year overall survival benefit and a comparable safety profile vs placebo plus chemotherapy jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Among patients with advanced #biliarytractcancer, durvalumab plus gemcitabine and cisplatin provided sustained 4-year overall survival benefit and a comparable safety profile vs placebo plus chemotherapy jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Among US cancer survivors, rates of lifestyle advice from health professionals remained stable 2011–2020, but advice was consistently associated with higher engagement in recommended behaviors. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Maintenance rucaparib provided >5-year progression-free survival for 16% of patients with #pancreaticcancer and BRCA/PALB2 variants; resistance mechanisms were detected in half of those with disease progression. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
From 2018 to 2023, use of minimally invasive surgery (MIS) for stage I #ovariancancer increased, but MIS was linked to higher intraoperative capsule rupture rates and lower overall survival when rupture occurred. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Increasing young-onset #colorectalcancer mortality in the US was concentrated in lower educational groups, highlighting widening disparities by socioeconomic status. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Genomic profiling of consecutive meningiomas found associations between copy number alterations, somatic variants, tumor grade, and patient characteristics, offering insights into prognosis and therapeutic vulnerability. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
A 60-year-old woman presented with progressive right lower extremity radiculopathy and numbness, a pigmented skin lesion on the right side of the chest, and right ankle jerk reflex. What is your diagnosis? jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
The AQUILA trial criteria classified more high-risk smoldering multiple myeloma but most had lower progression risk while the 2/20/20 model more accurately identified those likely to benefit from early treatment. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
After discontinuing pembrolizumab among patients with advanced #nonsmallcelllungcancer survival outcomes were high and subsequent immunotherapy use was rare. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Local salvage therapies alone for #prostatecancer recurrence after radiotherapy maintained >75% androgen deprivation therapy–free survival at 2 years with manageable rates of severe adverse events, supporting their use in selected patients. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Adult T-cell leukemia/lymphoma incidence among non-Hispanic Caribbean-born US residents approaches endemic region levels, with early-life human T-cell leukemia virus type 1 infection via maternal transmission identified as an actionable prevention target. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Patients with platinum-sensitive recurrent #ovariancancer and exceptional response to PARP inhibitors showed ≥78% ten-year progression-free survival, with low risk of myeloid cancers, regardless of maintenance duration.
jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… -
JAMA Oncology
@JAMAOnc
In advanced nonsquamous #nonsmallcelllungcancer, tiragolumab plus atezolizumab and chemotherapy did not improve progression-free or overall survival compared with pembrolizumab plus chemotherapy, with similar safety profiles.
jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… -
JAMA Oncology
@JAMAOnc
Early 18F-fluorodeoxyglucose positron emission tomography after 2 weeks of therapy identified patients with metastatic #breastcancer at higher risk for poor outcomes before standard CT. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Patients with #cancer aged 15 to 39 who received medical assistance in dying experienced escalating symptoms and often received palliative care later in the disease course compared to the general cancer population.
jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… -
JAMA Oncology
@JAMAOnc
The 9-valent #hpv vaccine was linked to reduced risk of #hpvrelatedcancers in males aged 9 to 26 years, with consistent protection in both the adolescent and young adult groups. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Pretreatment MRI findings including extraprostatic extension and seminal vesicle invasion were independently prognostic for recurrence, metastasis, and mortality after radical prostatectomy. #prostatecancer
jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… -
JAMA Oncology
@JAMAOnc
Clonal hematopoiesis of indeterminate potential (CHIP) was associated with higher risk of trastuzumab-related cardiotoxicity and heart failure in patients with #breastcancer.
jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… -
JAMA Oncology
@JAMAOnc
Among adults with lymphoma or myeloma, second primary malignant neoplasms after T-cell–engaging bispecific antibody therapy occurred in 3.5%, with most second primary malignant neoplasms being skin or hematologic cancers.
jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… -
JAMA Oncology
@JAMAOnc
A single-fraction 19 Gy SBRT regimen for localized #prostatecancer achieved 92.9% 3-year biochemical relapse-free survival, with grade 2 genitourinary and gastrointestinal adverse event rates below 10% and 5%, respectively, at 3 years.
jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… -
JAMA Oncology
@JAMAOnc
Sequential radiotherapy and immunotherapy (#irt) provided longer overall survival than concurrent iRT for newly diagnosed advanced non–small cell lung cancer, with additional benefit from chemotherapy.
jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… -
JAMA Oncology
@JAMAOnc
This JAMA Oncology Patient Page discusses benefits and risks of local consolidative therapy for metastatic #lungcancer and which patients might be considered for this treatment.
jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… -
JAMA Oncology
@JAMAOnc
A 58-year-old woman with #breastcancer with multiple prior courses of systemic treatments presented with hypotension, hypoxia, significant polyuria, and polydipsia. Mild thickening of the pituitary stalk was seen.
✍️ What is your diagnosis? jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… -
JAMA Oncology
@JAMAOnc
This Special Communication provides consensus recommendations on the acquisition, interpretation, and reporting of prostate magnetic resonance imaging for cancer screening. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Avelumab combined with methotrexate resulted in >95% durable remission and preserved #fertility in low-risk gestational trophoblastic #tumors, with a manageable safety profile.
jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… -
JAMA Oncology
@JAMAOnc
Sequential radiotherapy and immunotherapy (#irt) provided longer overall survival than concurrent iRT for newly diagnosed advanced non–small cell lung cancer, with additional benefit from chemotherapy.
jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… -
JAMA Oncology
@JAMAOnc
This JAMA Oncology Patient Page discusses benefits and risks of local consolidative therapy for metastatic #lungcancer and which patients might be considered for this treatment.
jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… -
JAMA Oncology
@JAMAOnc
Among patients with early age–onset #colorectalcancer in Texas, treatment delays longer than six weeks were associated with reduced survival, and language barriers represented a major risk factor contributing to delayed initiation of definitive therapy. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Sequential radiotherapy and immunotherapy (#irt) provided longer overall survival than concurrent iRT for newly diagnosed advanced non–small cell lung cancer, with additional benefit from chemotherapy.
jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… -
JAMA Oncology
@JAMAOnc
A phase 3 trial shows serplulimab plus chemotherapy improved overall survival and 4-year survival rates vs chemotherapy alone in extensive-stage small cell #lungcancer, with durable benefit and manageable safety. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Oral upadacitinib achieved rapid resolution and pruritus relief in severe immune checkpoint inhibitor–related #dermatitis, with no serious treatment-related adverse events.
jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… -
JAMA Oncology
@JAMAOnc
A meta-analysis found first-line chemoimmunotherapy provided longer overall and progression-free survival than PD-(L)1 inhibitor monotherapy in advanced #nsclc with high #pdl1, though with greater toxicity. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
A meta-analysis found first-line chemoimmunotherapy provided longer overall and progression-free survival than PD-(L)1 inhibitor monotherapy in advanced #nsclc with high #pdl1, though with greater toxicity. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
This JAMA Oncology Patient Page discusses benefits and risks of local consolidative therapy for metastatic #lungcancer and which patients might be considered for this treatment. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Oral upadacitinib achieved rapid resolution and pruritus relief in severe immune checkpoint inhibitor–related #dermatitis, with no serious treatment-related adverse events. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
From @JAMA_current: In resected non-small cell lung #cancer, adjuvant #nivolumab following standard care was not associated with improved survival or recurrence risk compared with observation, even in #tumors with high PD-L1 expression.
#asco26 @ASCO
jamanetwork.com/journals/jama/fullarticle/10.1001/jama.20… -
JAMA Oncology
@JAMAOnc
🌟Fovinaciclib for First‑Line Therapy for Advanced Breast Cancer: A Randomized Clinical Trial, presented today at #asco26
📖 Free to read online from @JAMAOnc
jamanetwork.com/pages/conferences-asco?linkId=952200559 -
JAMA Oncology
@JAMAOnc
A phase 3 trial demonstrated that fovinaciclib plus aromatase inhibitor showed significant and clinically improved progression-free survival with manageable safety in hormone receptor–positive, ERBB2-negative advanced #breastcancer.
#asco26 @ASCO
jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… -
JAMA Oncology
@JAMAOnc
A 69-year-old male patient presented with worsening new-onset oral ulcerations and pain. He had myelodysplastic syndrome and underwent an allogeneic hematopoietic stem cell transplant 18 months prior. What is your diagnosis? See the answer: jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
✨Impact of Population‑Based Pathogenic Variant Testing on Risk‑Based Breast Screening Recommendations: A Secondary Analysis of the WISDOM Study, presented today at #asco26
📖 Free to read online from @JAMAOnc
jamanetwork.com/pages/conferences-asco?linkId=952198931 -
JAMA Oncology
@JAMAOnc
Among women with breast cancer gene pathogenic variants (PV), most would not have received high-risk screening based on clinical or polygenic risk, supporting the need for germline PV testing in risk-based #breastcancer screening.
#asco26 @ASCO
jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… -
JAMA Oncology
@JAMAOnc
Older adults with advanced cancer mainly prioritized quality of life, but their treatment preferences were not associated with differences in survival, hospitalization, or adverse effects. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Study of veterans with cancer identified high rates of suicidal self-directed violence, with greatest risk in younger, female, American Indian or Alaska Native, and those with central nervous system, pancreas, liver, thyroid, or head and neck cancer.
jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… -
JAMA Oncology
@JAMAOnc
This Review examines the clinical utility of circulating tumor DNA assays for detecting minimal residual disease in patients with early-stage breast cancer.
jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… -
JAMA Oncology
@JAMAOnc
Sequential radiotherapy and immunotherapy (#irt) provided longer overall survival than concurrent iRT for newly diagnosed advanced non–small cell lung cancer, with additional benefit from chemotherapy.
jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… -
JAMA Oncology
@JAMAOnc
✨Attending #asco26?
🌟 Explore our attendee page for the latest articles
🎧 Listen to podcasts
📚 Get For Authors resources from @JAMA_current, @JAMAOnc, and @JAMANetworkOpen
jamanetwork.com/pages/conferences-asco?linkId=952193734 -
JAMA Oncology
@JAMAOnc
PRIME is a validated, interpretable #pancreaticcancer risk model using routine clinical data, supporting risk-based case-finding and integration with biomarker testing for early detection. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
In 2025, JAMA Oncology received 3738 manuscripts from 74 countries, with original scientific content impacting patient care, research, and policy.
Read the full Year in Review by JAMA Oncology Editor in Chief Mary L. (Nora) Disis, MD. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… -
JAMA Oncology
@JAMAOnc
Bireociclib plus fulvestrant improved progression-free survival and objective response in hormone receptor–positive, ERBB2-negative advanced #breastcancer after endocrine progression. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
P85-Ab testing outperformed conventional Epstein-Barr virus-based markers for outpatient nasopharyngeal carcinoma (NPC) diagnosis, with highest sensitivity and specificity among asymptomatic and NPC-nonspecific symptom populations. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Local salvage therapies alone for #prostatecancer recurrence after radiotherapy maintained >75% androgen deprivation therapy–free survival at 2 years with manageable rates of severe adverse events, supporting their use in selected patients.
jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… -
JAMA Oncology
@JAMAOnc
💬 Editorial: Stereotactic radiation offered modest symptom relief & better long-term neurocognitive outcomes than hippocampal-avoidance whole brain radiation, but was associated with higher rates of new brain metastases & salvage whole brain radiotherapy. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Relabeling grade group 1 #prostatecancer as precancerous was predicted to decrease US mortality, with six times more deaths avoided through increased screening than caused by reduced surveillance adherence. jamanetwork.com/journals/jamaoncology/fullarticle/?linkId…
-
JAMA Oncology
@JAMAOnc
Solid organ transplant recipients with a history of pretransplant cancer had higher risks of developing posttransplant cancers of the same type, including breast, lung, kidney, urinary bladder, liver, colorectal, and melanoma. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
A dose-reduced preoperative radiotherapy regimen (36 Gy in 18 fractions) for liposarcoma offered high local control and low rates of major late toxic effects in a phase 2 trial, supporting use in eligible patients.
jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… -
JAMA Oncology
@JAMAOnc
In patients with advanced solid tumors, survival improved when genomic therapy matching was based on robust clinical trial evidence; investigational or repurposed biomarker matches did not provide benefit. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Relabeling grade group 1 #prostatecancer as precancerous was predicted to decrease US mortality, with six times more deaths avoided through increased screening than caused by reduced surveillance adherence. jamanetwork.com/journals/jamaoncology/fullarticle/?linkId…
-
JAMA Oncology
@JAMAOnc
Adding intraperitoneal paclitaxel to intravenous paclitaxel plus S-1 improved overall survival for #gastriccancer with peritoneal metastasis, with safety profiles comparable to intravenous-only therapy. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Early-stage #lungcancer diagnoses increased nationally and in all states after screening recommendations in 2013, but fewer than 1 in 5 eligible adults are up to date with screening. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
High modifiable risk factors were more strongly associated with #pancreaticcancer for adults aged <60 years, especially those with high genetic risk, supporting early-life prevention strategies.
jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… -
JAMA Oncology
@JAMAOnc
A dose-reduced preoperative radiotherapy regimen (36 Gy in 18 fractions) for liposarcoma offered high local control and low rates of major late toxic effects in a phase 2 trial, supporting use in eligible patients.
#estro26 @ESTRO_RT
jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… -
JAMA Oncology
@JAMAOnc
First-line CDK4/6 inhibitor use did not improve overall survival vs second-line use in advanced hormone receptor–positive, ERBB2-negative #breastcancer and increased grade ≥3 adverse events.
jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… -
JAMA Oncology
@JAMAOnc
First-line CDK4/6 inhibitor use did not improve overall survival vs second-line use in advanced hormone receptor–positive, ERBB2-negative #breastcancer and increased grade ≥3 adverse events.
jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… -
JAMA Oncology
@JAMAOnc
This JAMA Oncology Patient Page describes different types of common mouth problems during #cancer treatment and how to care for them.
jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… -
JAMA Oncology
@JAMAOnc
Tumor-infiltrating clonal hematopoiesis was detected in 18% of patients with solid tumors and associated with older age, prior cytotoxic chemotherapy, and reduced overall survival, especially in breast cancer. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Nearly half of older adults with metastatic #lungcancer did not receive systemic therapy, and treatment rates changed minimally from 2006 to 2021.
jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… -
JAMA Oncology
@JAMAOnc
Tumor-infiltrating clonal hematopoiesis was detected in 18% of patients with solid tumors and associated with older age, prior cytotoxic chemotherapy, and reduced overall survival, especially in breast cancer. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Receipt of prostate-specific membrane antigen positron emission tomography for #prostatecancer staging was associated w/higher initiation rates of androgen receptor pathway inhibitor therapy and increased use of systemic treatment compared to bone scans. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Nearly half of older adults with metastatic #lungcancer did not receive systemic therapy, and treatment rates changed minimally from 2006 to 2021. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Tumor-infiltrating clonal hematopoiesis was detected in 18% of patients with solid tumors and associated with older age, prior cytotoxic chemotherapy, and reduced overall survival, especially in breast cancer. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Among US cancer survivors, rates of lifestyle advice from health professionals remained stable 2011–2020, but advice was consistently associated with higher engagement in recommended behaviors. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
In advanced nonsquamous #nonsmallcelllungcancer, tiragolumab plus atezolizumab and chemotherapy did not improve progression-free or overall survival compared with pembrolizumab plus chemotherapy, with similar safety profiles. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Maintenance rucaparib provided >5-year progression-free survival for 16% of patients with #pancreaticcancer and BRCA/PALB2 variants; resistance mechanisms were detected in half of those with disease progression. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
A 60-year-old woman presented with progressive right lower extremity radiculopathy and numbness, a pigmented skin lesion on the right side of the chest, and right ankle jerk reflex.
What is your diagnosis? jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… -
JAMA Oncology
@JAMAOnc
Adult T-cell leukemia/lymphoma incidence among non-Hispanic Caribbean-born US residents approaches endemic region levels, with early-life human T-cell leukemia virus type 1 infection via maternal transmission identified as an actionable prevention target. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Local salvage therapies alone for #prostatecancer recurrence after radiotherapy maintained >75% androgen deprivation therapy–free survival at 2 years with manageable rates of severe adverse events, supporting their use in selected patients. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
In advanced nonsquamous #nonsmallcelllungcancer, tiragolumab plus atezolizumab and chemotherapy did not improve progression-free or overall survival compared with pembrolizumab plus chemotherapy, with similar safety profiles. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
📄 This JAMA Oncology Patient Page describes different types of common mouth problems during #cancer treatment and how to care for them. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
This study demonstrates that therapy with Bruton tyrosine kinase inhibitors for B-cell malignant diseases significantly increases the risk of pericardial effusion and several other cardiovascular events compared with alternative regimens. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Adolescent and young adult women with prior cervical high-grade squamous intraepithelial lesions had elevated risks of #cvd, myocardial infarction, heart failure, and cerebrovascular mortality compared with matched controls. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
BrECADD produced better health-related quality of life than escalated BEACOPP in advanced-stage #hodgkinlymphoma, with fewer chemotherapy-related symptoms and improved functioning. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
A 67-year-old man with a history of λ light-chain multiple myeloma presents with increased serum-free λ light chain levels. What is your diagnosis? jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Adjuvant imatinib was associated with longer recurrence-free and overall survival in high-risk patients with KIT exon 9–mutated gastrointestinal stromal tumors, with similar outcomes for 400 mg/d vs 800 mg/d dosing. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
The AQUILA trial criteria classified more high-risk smoldering multiple myeloma but most had lower progression risk while the 2/20/20 model more accurately identified those likely to benefit from early treatment. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Open-source #ai models for #lungcancer EGFR mutation prediction showed high accuracy overall but reduced performance in Asian patients and pleural samples, indicating the need for broader validation. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
From @JAMA_current: Tucidinostat plus standard therapy increased complete response rates in MYC/BCL2 double-expressor #diffuselargebcelllymphoma, with higher but manageable toxicity compared with standard treatment alone.
jamanetwork.com/journals/jama/fullarticle/10.1001/jama.20… -
JAMA Oncology
@JAMAOnc
Fifteen-year follow-up of the SWOG S0016 trial demonstrates that 42% of patients with advanced-stage #follicularlymphoma treated with CHOP-based chemoimmunotherapy achieve functional cure. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
From 2018 to 2023, use of minimally invasive surgery (MIS) for stage I #ovariancancer increased, but MIS was linked to higher intraoperative capsule rupture rates and lower overall survival when rupture occurred. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
💬Editorial: SONIA demonstrates that reserving #cdk46 inhibitors for progression is generally appropriate for postmenopausal patients with hormone receptor–positive #breastcancer, supporting individualized sequencing and shared decision-making. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
The AQUILA trial criteria classified more high-risk smoldering multiple myeloma but most had lower progression risk while the 2/20/20 model more accurately identified those likely to benefit from early treatment. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
In recurrent or metastatic #nasopharyngealcancer, tislelizumab plus chemotherapy led to longer overall survival and durable progression-free survival compared with placebo plus chemotherapy. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
First-line CDK4/6 inhibitor use did not improve overall survival vs second-line use in advanced hormone receptor–positive, ERBB2-negative #breastcancer and increased grade ≥3 adverse events.
jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… -
JAMA Oncology
@JAMAOnc
💬 Editorial: Most women in the WISDOM trial preferred tailored, risk-based #breastcancer screening, highlighting its patient acceptability and supporting a shift from age-based protocols. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
In localized radiorecurrent #prostatecancer, salvage focal therapy provided similar 10-year survival outcomes as radical prostatectomy but resulted in substantially fewer perioperative complications. @AJWLight @LondonProstate1 @TaimurShah jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Individuals diagnosed with cancer in 2020 and 2021 had lower 1-year survival than before the pandemic, with greatest impact seen in older adults and non-Hispanic minority groups. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Increasing young-onset #colorectalcancer mortality in the US was concentrated in lower educational groups, highlighting widening disparities by socioeconomic status. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Early 18F-fluorodeoxyglucose positron emission tomography after 2 weeks of therapy identified patients w/ metastatic #breastcancer at higher risk for poor outcomes before standard CT, supporting its use to enhance prognostication and management decisions. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Bireociclib plus fulvestrant improved progression-free survival and objective response in hormone receptor–positive, ERBB2-negative advanced #breastcancer after endocrine progression.
jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… -
JAMA Oncology
@JAMAOnc
Patients with #cancer aged 15 to 39 who received medical assistance in dying experienced escalating symptoms and often received palliative care later in the disease course compared to the general cancer population. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology reposted
JAMA
@JAMA_current
Today, the JAMA Network launches @JAMAplusTrials, a new online platform that highlights the vision, innovation, and resilience of clinical trial research.
Designed for clinicians, investigators, trainees, and others engaged in clinical research worldwide, JAMA+ Trials is an interdisciplinary resource for enhancing insights and promoting dialogue in clinical trial research. 🧵 -
JAMA Oncology reposted
UCSF Neurosurgery
@NeurosurgUCSF
In a new @JAMAOnc study, @LabRaleigh and colleagues report the results from a prospective genomic profiling analysis of more than 1100 meningiomas. Their findings could help guide evolving diagnostic criteria and clinical trial design: jamanetwork.com/journals/jamaoncology/fullarticle/2847528
@UCSFRadOnc -
JAMA Oncology
@JAMAOnc
The 9-valent #hpv vaccine was linked to reduced risk of #hpvrelatedcancers in males aged 9 to 26 years, with consistent protection in both the adolescent and young adult groups. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Genomic profiling of consecutive meningiomas found associations between copy number alterations, somatic variants, tumor grade, and patient characteristics, offering insights into prognosis and therapeutic vulnerability. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
After discontinuing pembrolizumab among patients with advanced #nonsmallcelllungcancer survival outcomes were high and subsequent immunotherapy use was rare.
jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… -
JAMA Oncology
@JAMAOnc
The 9-valent #hpv vaccine was linked to reduced risk of #hpvrelatedcancers in males aged 9 to 26 years, with consistent protection in both the adolescent and young adult groups. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Bireociclib plus fulvestrant improved progression-free survival and objective response in hormone receptor–positive, ERBB2-negative advanced #breastcancer after endocrine progression.
jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… -
JAMA Oncology
@JAMAOnc
Clonal hematopoiesis of indeterminate potential (CHIP) was associated with higher risk of trastuzumab-related cardiotoxicity and heart failure in patients with #breastcancer.
jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… -
JAMA Oncology
@JAMAOnc
Pretreatment MRI findings including extraprostatic extension and seminal vesicle invasion were independently prognostic for recurrence, metastasis, and mortality after radical prostatectomy. #prostatecancer
jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… -
JAMA Oncology
@JAMAOnc
The addition of camrelizumab to chemotherapy produced statistically significant and clinically meaningful 5-year OS benefits compared with chemotherapy alone in the first-line treatment of recurrent or metastatic nasopharyngeal carcinoma. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Low-dose aspirin in older adults was not associated with lower #cancer incidence over 8.6 years, and cancer mortality risk did not persist beyond the exposure period. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Among patients with immune checkpoint inhibitor–related cutaneous adverse events, dupilumab therapy was associated with lower 5-year mortality compared to no dupilumab or systemic corticosteroids. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Bireociclib plus fulvestrant improved progression-free survival and objective response in hormone receptor–positive, ERBB2-negative advanced #breastcancer after endocrine progression.
jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… -
JAMA Oncology
@JAMAOnc
Incidentally detected spleen length ≥140 mm or volume ≥500 mL was associated with markedly elevated 5-year risk for hematologic cancer, liver cancer, and cirrhosis in adults from Denmark and the UK. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
The 2025 federal #medicaid restrictions are projected to cause over 1 million missed #cancerscreening exams and over 150 excess #cancer deaths within 2 years, with substantial impact on younger and vulnerable adults. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
💬 Editorial: Stereotactic radiation offered modest symptom relief & better long-term neurocognitive outcomes than hippocampal-avoidance whole brain radiation, but was associated w/ higher rates of new brain metastases & salvage whole brain radiotherapy.
jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… -
JAMA Oncology
@JAMAOnc
From @JAMA_current: The Medicare #oncology Care Model (OCM) was associated with modest reductions in Medicare payments for beneficiaries receiving #chemotherapy for cancer; however, overall program costs exceeded these spending reductions.
jamanetwork.com/journals/jama/fullarticle/10.1001/jama.20… -
JAMA Oncology
@JAMAOnc
Guideline-adherent lymph node dissection provided a small survival benefit for patients with high-grade or no lepidic pattern #lungadenocarcinoma, but not for those with lepidic pattern alone. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
📄 This JAMA Oncology Patient Page discusses benefits and risks of local consolidative therapy for metastatic #lungcancer and which patients might be considered for this treatment.
jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… -
JAMA Oncology
@JAMAOnc
Ocular toxic effects including keratopathy, blurred vision, cataract progression, and uveitis were common but generally reversible during mirvetuximab soravtansine therapy for FRα-positive gynecologic cancers. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
PRIME is a validated, interpretable #pancreaticcancer risk model using routine clinical data, supporting risk-based case-finding and integration with biomarker testing for early detection.
jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… -
JAMA Oncology
@JAMAOnc
A 52-year-old woman had presented with persistent inflammatory edema of the lower limb and a history of squamous cell carcinoma.
What is your diagnosis?
jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… -
JAMA Oncology
@JAMAOnc
Among men with #prostatecancer undergoing hormone therapy, #sglt2 inhibitor use was associated with lower risk of treatment failure and delayed progression compared with nonuse, supporting potential adjunctive benefit. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Sequential radiotherapy and immunotherapy (#irt) provided longer overall survival than concurrent iRT for newly diagnosed advanced non–small cell lung cancer, with additional benefit from chemotherapy.
jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… -
JAMA Oncology
@JAMAOnc
A 52-year-old woman had presented with persistent inflammatory edema of the lower limb and a history of squamous cell carcinoma. What is your diagnosis? jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
💬 Editorial: MELATORCH trial supports PD-1 blockade as standard care over chemotherapy for advanced acral melanoma, yet limited long-term benefit signals the need for novel therapeutic strategies.
jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… -
JAMA Oncology
@JAMAOnc
In a phase 3 trial, toripalimab improved progression-free survival over dacarbazine as first-line treatment in advanced melanoma predominantly of acral subtype, with an acceptable safety profile. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
CHIP was associated with increased heart failure and ischemic cardiovascular disease risk after #cancer therapy in patients with solid tumors, especially among those with higher #chemotherapy exposure. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Review: Adjuvant #immunotherapy was often cost-effective in #cancercare, particularly for early-stage/high-risk cases, but findings varied by cancer type, drug price, and country-specific thresholds.
jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… -
JAMA Oncology
@JAMAOnc
Bireociclib plus fulvestrant improved progression-free survival and objective response in hormone receptor–positive, ERBB2-negative advanced #breastcancer after endocrine progression.
jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… -
JAMA Oncology
@JAMAOnc
In 2025, JAMA Oncology received 3738 manuscripts from 74 countries, with original scientific content impacting patient care, research, and policy.
Read "JAMA Oncology—The Year in Review, 2025" by Editor in Chief Mary L. (Nora) Disis, MD.
jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… -
JAMA Oncology
@JAMAOnc
P85-Ab testing outperformed conventional Epstein-Barr virus-based markers for outpatient nasopharyngeal carcinoma (NPC) diagnosis, with highest sensitivity and specificity among asymptomatic and NPC-nonspecific symptom populations.
jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… -
JAMA Oncology
@JAMAOnc
Among patients with low-risk #endometrialcancer, presence of isolated tumor cells in regional lymph nodes was linked to lower 4-year survival without adjuvant therapy compared to node-negative cases.
jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… -
JAMA Oncology
@JAMAOnc
A 69-year-old male patient presented with worsening new-onset oral ulcerations and pain. He had myelodysplastic syndrome and underwent an allogeneic hematopoietic stem cell transplant 18 months prior.
What is your diagnosis? See the answer: jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… -
JAMA Oncology
@JAMAOnc
Solid #organtransplant recipients with a history of pretransplant #cancer had higher risks of developing posttransplant cancers of the same type, including breast, lung, kidney, urinary bladder, liver, colorectal, and melanoma.
jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… -
JAMA Oncology
@JAMAOnc
Solid #organtransplant recipients with a history of pretransplant #cancer had higher risks of developing posttransplant cancers of the same type, including breast, lung, kidney, urinary bladder, liver, colorectal, and melanoma.
jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… -
JAMA Oncology
@JAMAOnc
From @JAMA_current: #obesity is associated with higher risk for 12 #cancer types and accounts for approximately 10% of annual new cancer cases in the US.
📄 This Review summarizes the biological pathways connecting obesity and cancer development. jamanetwork.com/journals/jama/fullarticle/10.1001/jama.20… -
JAMA Oncology
@JAMAOnc
Older adults with advanced #cancer mainly prioritized quality of life, but their treatment preferences were not associated with differences in survival, hospitalization, or adverse effects.
jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… -
JAMA Oncology
@JAMAOnc
📄 This JAMA Oncology Patient Page describes different types of common mouth problems during #cancer treatment and how to care for them.
jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… -
JAMA Oncology
@JAMAOnc
Oral upadacitinib achieved rapid resolution and pruritus relief in severe immune checkpoint inhibitor–related #dermatitis, with no serious treatment-related adverse events.
jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… -
JAMA Oncology
@JAMAOnc
Older adults with advanced cancer mainly prioritized quality of life, but their treatment preferences were not associated with differences in survival, hospitalization, or adverse effects.
jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… -
JAMA Oncology
@JAMAOnc
In patients with advanced solid tumors, survival improved when genomic therapy matching was based on robust clinical trial evidence; investigational or repurposed biomarker matches did not provide benefit.
jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… -
JAMA Oncology
@JAMAOnc
Definitive radiotherapy with or without chemotherapy in anterior nasal cavity cancers achieved high rates of long-term organ preservation & favorable local recurrence rates for patients who declined rhinectomy or had unresectable disease. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
📢 This Special Communication describes obstacles to sharing data and biospecimens and proposes strategies to enhance access and collaboration. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Adjuvant imatinib was associated with longer recurrence-free and overall survival in high-risk patients with KIT exon 9–mutated gastrointestinal stromal tumors, with similar outcomes for 400 mg/d vs 800 mg/d dosing.
jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… -
JAMA Oncology
@JAMAOnc
Immune checkpoint inhibitor–induced #diabetes occurred in 0.52% of patients across 158 National Cancer Institute trials, with higher incidence for combination immunotherapy and lower rates when combined with #chemotherapy. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
💬 Editorial: Most women in the WISDOM trial preferred tailored, risk-based #breastcancer screening, highlighting its patient acceptability and supporting a shift from age-based protocols.
jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… -
JAMA Oncology
@JAMAOnc
Among over 7000 patients with #cancer, higher baseline fatigue before systemic therapy was linked to an increased risk of severe, life-threatening, and fatal adverse events. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Fifteen-year follow-up of the SWOG S0016 trial demonstrates that 42% of patients with advanced-stage #follicularlymphoma treated with CHOP-based chemoimmunotherapy achieve functional cure.
jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… -
JAMA Oncology
@JAMAOnc
Quadrivalent #hpv vaccination was associated with lower rates of high-grade vulvovaginal lesions, especially among women vaccinated at ages 10 to 16, in a large cohort study. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
In recurrent or metastatic #nasopharyngealcancer, tislelizumab plus chemotherapy led to longer overall survival and durable progression-free survival compared with placebo plus chemotherapy.
jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… -
JAMA Oncology
@JAMAOnc
💬 Viewpoint: Effective stroke care for patients with cancer requires rapid interdisciplinary communication, clear documentation of prognosis and goals of care, and urgent application of acute stroke therapies. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
The MyLungHealth randomized trial found that digital tools improved eligibility assessment and CT ordering for #lungcancer screening, but gains in scan completion were limited. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
💬 Viewpoint: Nonfinancial conflicts, including relationships and beliefs, can shape #oncology research outcomes, highlighting the need for routine disclosure and management to support scientific credibility.
jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… -
JAMA Oncology
@JAMAOnc
First-line CDK4/6 inhibitor use did not improve overall survival vs second-line use in advanced hormone receptor–positive, ERBB2-negative #breastcancer and increased grade ≥3 adverse events.
jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… -
JAMA Oncology
@JAMAOnc
💬 Editorial: Cancer-related cognitive impairment frequently affects #breastcancer survivors and may persist for years after treatment, with greater risk among those receiving chemoendocrine therapy. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
In this secondary analysis of the RxPONDER trial, chemoendocrine therapy was associated with greater and more persistent self-reported cognitive impairment than endocrine therapy alone in both pre- and postmenopausal women with #breastcancer.
jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… -
JAMA Oncology
@JAMAOnc
This study demonstrates that therapy with Bruton tyrosine kinase inhibitors for B-cell malignant diseases significantly increases the risk of pericardial effusion and several other cardiovascular events compared with alternative regimens.
jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… -
JAMA Oncology
@JAMAOnc
💬 Editorial: Precision adjuvant therapy for stage III #coloncancer may be enhanced through molecular profiling for ctDNA status and PIK3CA mutation, informing use of celecoxib or aspirin alongside standard treatment.
jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… -
JAMA Oncology
@JAMAOnc
ctDNA status may help identify which patients benefit from adjuvant celecoxib, supporting personalized treatment approaches in #coloncancer. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Adolescent and young adult women with prior cervical high-grade squamous intraepithelial lesions had elevated risks of #cvd, myocardial infarction, heart failure, and cerebrovascular mortality compared with matched controls.
jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… -
JAMA Oncology
@JAMAOnc
Adolescent and young adult women with prior cervical high-grade squamous intraepithelial lesions had elevated risks of #cvd, myocardial infarction, heart failure, and cerebrovascular mortality compared with matched controls.
jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… -
JAMA Oncology
@JAMAOnc
First-line CDK4/6 inhibitor use did not improve overall survival vs second-line use in advanced hormone receptor–positive, ERBB2-negative #breastcancer and increased grade ≥3 adverse events.
jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… -
JAMA Oncology
@JAMAOnc
💬Editorial: SONIA demonstrates that reserving #cdk46 inhibitors for progression is generally appropriate for postmenopausal patients with hormone receptor–positive #breastcancer, supporting individualized sequencing and shared decision-making.
jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… -
JAMA Oncology
@JAMAOnc
First-line CDK4/6 inhibitor use did not improve overall survival vs second-line use in advanced hormone receptor–positive, ERBB2-negative #breastcancer and increased grade ≥3 adverse events.
jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… -
JAMA Oncology
@JAMAOnc
Open-source #ai models for #lungcancer EGFR mutation prediction showed high accuracy overall but reduced performance in Asian patients and pleural samples, indicating the need for broader validation.
jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… -
JAMA Oncology
@JAMAOnc
In localized radiorecurrent #prostatecancer, salvage focal therapy provided similar 10-year survival outcomes as radical prostatectomy but resulted in substantially fewer perioperative complications.
jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… -
JAMA Oncology
@JAMAOnc
A 67-year-old man with a history of λ light-chain multiple myeloma presents with increased serum-free λ light chain levels.
What is your diagnosis?
jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… -
JAMA Oncology
@JAMAOnc
Open-source #ai models for #lungcancer EGFR mutation prediction showed high accuracy overall but reduced performance in Asian patients and pleural samples, indicating the need for broader validation.
jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… -
JAMA Oncology
@JAMAOnc
In localized radiorecurrent #prostatecancer, salvage focal therapy provided similar 10-year survival outcomes as radical prostatectomy but resulted in substantially fewer perioperative complications.
jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… -
JAMA Oncology
@JAMAOnc
Individuals diagnosed with cancer in 2020 and 2021 had lower 1-year survival than before the pandemic, with greatest impact seen in older adults and non-Hispanic minority groups.
jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… -
JAMA Oncology
@JAMAOnc
Individuals diagnosed with cancer in 2020 and 2021 had lower 1-year survival than before the pandemic, with greatest impact seen in older adults and non-Hispanic minority groups.
jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… -
JAMA Oncology
@JAMAOnc
Individuals diagnosed with cancer in 2020 and 2021 had lower 1-year survival than before the pandemic, with greatest impact seen in older adults and non-Hispanic minority groups.
jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… -
JAMA Oncology
@JAMAOnc
Individuals diagnosed with cancer in 2020 and 2021 had lower 1-year survival than before the pandemic, with greatest impact seen in older adults and non-Hispanic minority groups.
jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… -
JAMA Oncology
@JAMAOnc
Individuals diagnosed with cancer in 2020 and 2021 had lower 1-year survival than before the pandemic, with greatest impact seen in older adults and non-Hispanic minority groups.
jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… -
JAMA Oncology
@JAMAOnc
BrECADD produced better health-related quality of life than escalated BEACOPP in advanced-stage #hodgkinlymphoma, with fewer chemotherapy-related symptoms and improved functioning.
jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… -
JAMA Oncology
@JAMAOnc
Individuals diagnosed with cancer in 2020 and 2021 had lower 1-year survival than before the pandemic, with greatest impact seen in older adults and non-Hispanic minority groups.
jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… -
JAMA Oncology
@JAMAOnc
Low-dose aspirin in older adults was not associated with lower #cancer incidence over 8.6 years, and cancer mortality risk did not persist beyond the exposure period.
jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… -
JAMA Oncology
@JAMAOnc
📢 @JAMA_current Special Communication: Opportunistic salpingectomy during pelvic or selected abdominal surgery is associated with lower risk of tubo-ovarian #carcinoma and minimal #surgical risk, but data on long-term #ovarian function remain limited.
jamanetwork.com/journals/jama/fullarticle/10.1001/jama.20… -
JAMA Oncology
@JAMAOnc
This JAMA Oncology Patient Page describes the 3 main types of urinary diversions and care required after surgery to ensure an active and fulfilling life.
jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… -
JAMA Oncology reposted
Bibek Aryal MD, PhD
@bibekaryal3
🔥 Hot off the press!
How can we conquer cancer if we don’t know how many people have it?
🧵 My new Viewpoint in @JAMAOnc why cancer registries are a moral imperative—not just a technical tool. -
JAMA Oncology reposted
Eric Topol
@EricTopol
In follow-up of a randomized trial of low-dose aspirin in >19,000 older adults, cancer was not prevented and mortality related to cancer was increased @JAMAOnc
jamanetwork.com/journals/jamaoncology/fullarticle/2844193 -
JAMA Oncology reposted
Dana-Farber’s Breast Oncology Center
@DFCI_BreastOnc
Check out this recent @JAMAOnc paper on cognitive impairment and chemoendocrine vs endocrine therapy in pre- and postmenopausal women: A Secondary Analysis of the #rxponder Randomized Clinical Trial
👉pubmed.ncbi.nlm.nih.gov/41379459/
@irenekangmd @jrgralow @hoosierdfh @nlinmd @KalinskyKevin -
JAMA Oncology reposted
JAMA Cardiology
@JAMACardio
Today we welcome Barbara Casadei, MD, DPhil, from @ImperialNHLI, as Editor in Chief.
An internationally recognized clinician‑scientist, Dr Casadei brings extensive experience in global cardiovascular research. 🧵 -
JAMA Oncology
@JAMAOnc
The addition of camrelizumab to chemotherapy produced statistically significant and clinically meaningful 5-year OS benefits compared with chemotherapy alone in the first-line treatment of recurrent or metastatic nasopharyngeal carcinoma.
jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… -
JAMA Oncology
@JAMAOnc
This JAMA Oncology Patient Page describes the 3 main types of urinary diversions and care required after surgery to ensure an active and fulfilling life.
jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… -
JAMA Oncology
@JAMAOnc
Low-dose aspirin in older adults was not associated with lower #cancer incidence over 8.6 years, and cancer mortality risk did not persist beyond the exposure period.
jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… -
JAMA Oncology
@JAMAOnc
In active surveillance for #prostatecancer, #mri was most reliable for ruling out significant cancer in low PSA density cases but failed to achieve sufficient accuracy in broader populations.
jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… -
JAMA Oncology
@JAMAOnc
The addition of camrelizumab to chemotherapy produced statistically significant and clinically meaningful 5-year OS benefits compared with chemotherapy alone in the first-line treatment of recurrent or metastatic nasopharyngeal carcinoma.
jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… -
JAMA Oncology
@JAMAOnc
In early 2025, the National Cancer Institute terminated 181 extramural grants, totaling more than $640 million in awards. Terminations targeted primarily basic science, general oncology, and early-career investigators.
jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… -
JAMA Oncology
@JAMAOnc
Low-dose aspirin in older adults was not associated with lower #cancer incidence over 8.6 years, and cancer mortality risk did not persist beyond the exposure period.
jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… -
JAMA Oncology
@JAMAOnc
For adults with metastatic HER2-positive #biliarytractcancer, zanidatamab led to longer overall survival and reduced pain, supporting its role as a precision therapy option. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Among patients with advanced urothelial cancer, upfront enfortumab vedotin dose reduction was linked to a 50% reduction in treatment interruption risk but did not compromise overall survival. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Semaglutide and tirzepatide prescriptions for obesity have increased among patients with preexisting cancer, with notable variation by cancer type and absence of cancer-specific guidelines. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Cross-disciplinary international position statement summarizes the current understanding of CV toxic effects associated with ICI therapy, including strategies for diagnosis, treatment, and potential rechallenge and an outline of relevant knowledge gaps. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
In a nonrandomized phase 2 trial of adults with advanced dMMR/MSI-H noncolorectal cancers, combined nivolumab/ipilimumab showed an objective response rate of 63% and 6-month progression-free survival rate of 71%.
jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… -
JAMA Oncology
@JAMAOnc
Among women under 50, those with the highest ultraprocessed food intake had 45% higher odds of early-onset colorectal conventional adenomas versus those with the lowest intake; no significant association was seen for serrated lesions. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Phase 2 trial finds lorlatinib yielded a 73% objective response rate and median progression-free survival of 53.6 months in TKI-naive advanced ROS1-positive NSCLC. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
💬 Editorial: Metastatic recurrence nearly triples mortality risk in #breastcancer among young adults and increases death risk in sarcoma and colorectal cancer—highlighting the need for earlier detection and novel treatments. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Among adolescents and young adults with #cancer, 9.5% of patients with earlier-stage cancer experienced metastatic recurrence within five years, with the highest rates in sarcoma (24.5%) and colorectal cancer (21.8%).
jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… -
JAMA Oncology
@JAMAOnc
Among patients with immune checkpoint inhibitor–related cutaneous adverse events, dupilumab therapy was associated with lower 5-year mortality compared to no dupilumab or systemic corticosteroids.
jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… -
JAMA Oncology
@JAMAOnc
💬 Viewpoint: The badscopal effect following ablative radiotherapy signals not failure but biological reorganization, prompting serial metastasis-directed therapy in selected patients. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
This Review outlines health gains and economic value, and identifies where future research, pricing reform, or prioritization are needed to support evidence-informed policymaking and sustainable use of immunotherapy in cancer treatment pathways.
jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… -
JAMA Oncology
@JAMAOnc
The IMPACT tool accurately stratifies incidental meningioma patients by progression risk, supporting early intervention for high-risk, monitoring for medium-risk, and safe discharge for low-risk individuals.
jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… -
JAMA Oncology
@JAMAOnc
Meta-analysis: Among patients with intermediate-, high-, or very high-risk prostate cancer, the ideal duration of ADT with radiotherapy demonstrated nonlinear benefits, with diminished gains after 12 months and variation in benefit by risk group. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
💬 Viewpoint: #medicaid cuts and work requirements in the 2025 budget law risk reduced access to cancer prevention, delayed diagnoses, later-stage disease at presentation, and caused worse cancer outcomes.
jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… -
JAMA Oncology
@JAMAOnc
Among men with #prostatecancer undergoing hormone therapy, #sglt2 inhibitor use was associated with lower risk of treatment failure and delayed progression compared with nonuse, supporting potential adjunctive benefit.
jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… -
JAMA Oncology
@JAMAOnc
The 2025 federal #medicaid restrictions are projected to cause over 1 million missed #cancerscreening exams and over 150 excess #cancer deaths within 2 years, with substantial impact on younger and vulnerable adults.
jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… -
JAMA Oncology
@JAMAOnc
CHIP was associated with increased heart failure and ischemic cardiovascular disease risk after #cancer therapy in patients with solid tumors, especially among those with higher #chemotherapy exposure.
jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… -
JAMA Oncology
@JAMAOnc
Among women under 50, those with the highest ultraprocessed food intake had 45% higher odds of early-onset colorectal conventional adenomas versus those with the lowest intake; no significant association was seen for serrated lesions. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Guideline-adherent lymph node dissection provided a small survival benefit for patients with high-grade or no lepidic pattern #lungadenocarcinoma, but not for those with lepidic pattern alone. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
In a nonrandomized phase 2 trial of adults with advanced dMMR/MSI-H noncolorectal cancers, combined nivolumab/ipilimumab showed an objective response rate of 63% and 6-month progression-free survival rate of 71%.
jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… -
JAMA Oncology
@JAMAOnc
Guideline-adherent lymph node dissection provided a small survival benefit for patients with high-grade or no lepidic pattern #lungadenocarcinoma, but not for those with lepidic pattern alone. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Older age in unrelated donors linked to lower survival in allogeneic hematopoietic cell transplant with conventional calcineurin inhibitor-based graft-vs-host disease prophylaxis, but this association is mitigated with posttransplant cyclophosphamide.
jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… -
JAMA Oncology
@JAMAOnc
Incidentally detected spleen length ≥140 mm or volume ≥500 mL was associated with markedly elevated 5-year risk for hematologic cancer, liver cancer, and cirrhosis in adults from Denmark and the UK. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Guideline-adherent lymph node dissection provided a small survival benefit for patients with high-grade or no lepidic pattern #lungadenocarcinoma, but not for those with lepidic pattern alone. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
The 2025 federal #medicaid restrictions are projected to cause over 1 million missed #cancerscreening exams and over 150 excess #cancer deaths within 2 years, with substantial impact on younger and vulnerable adults. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Among men with #prostatecancer undergoing hormone therapy, #sglt2 inhibitor use was associated with lower risk of treatment failure and delayed progression compared with nonuse, supporting potential adjunctive benefit. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
CHIP was associated with increased heart failure and ischemic cardiovascular disease risk after #cancer therapy in patients with solid tumors, especially among those with higher #chemotherapy exposure. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Gastric cancer is the fifth most diagnosed #cancer and the fifth leading cause of cancer-related deaths worldwide.
This @JAMA_current Review summarizes the epidemiology, pathophysiology, diagnosis, and management of #gastriccancer.
jamanetwork.com/journals/jama/fullarticle/10.1001/jama.20… -
JAMA Oncology
@JAMAOnc
Among patients with advanced urothelial cancer, upfront enfortumab vedotin dose reduction was linked to a 50% reduction in treatment interruption risk but did not compromise overall survival.
jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… -
JAMA Oncology
@JAMAOnc
Meta-analysis: Among patients with intermediate-, high-, or very high-risk prostate cancer, the ideal duration of ADT with radiotherapy demonstrated nonlinear benefits, with diminished gains after 12 months and variation in benefit by risk group.
jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… -
JAMA Oncology
@JAMAOnc
Ocular toxic effects including keratopathy, blurred vision, cataract progression, and uveitis were common but generally reversible during mirvetuximab soravtansine therapy for FRα-positive gynecologic cancers. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Sarcomas comprise a heterogeneous group of malignant neoplasms that include genomically simple and genomically complex subtypes. This consensus provides guidelines for efficient, rational use of next-generation sequencing in their clinical management.
jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… -
JAMA Oncology
@JAMAOnc
A 52-year-old woman had presented with persistent inflammatory edema of the lower limb and a history of squamous cell #carcinoma.
What is your diagnosis? jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… -
JAMA Oncology
@JAMAOnc
Editorial: MELATORCH trial supports PD-1 blockade as standard care over chemotherapy for advanced acral melanoma, yet limited long-term benefit signals the need for novel therapeutic strategies. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
In a phase 3 trial, toripalimab improved progression-free survival over dacarbazine as first-line treatment in advanced #melanoma predominantly of acral subtype, with an acceptable safety profile. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Sarcomas comprise a heterogeneous group of malignant neoplasms that include genomically simple and genomically complex subtypes. This consensus provides guidelines for efficient, rational use of next-generation sequencing in their clinical management.
jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… -
JAMA Oncology
@JAMAOnc
Dexrazoxane use in pediatric AML rose from 0.5% to 98.5% between 2010 and 2021, coinciding with a 50% reduction in ICU-level cardiovascular care, supporting rapid adoption of dexrazoxane for cardioprotection with intensive chemotherapy. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Cribriform morphology predicted 15-year metastasis in #prostatecancer, with radiotherapy plus neoadjuvant ADT reducing this risk, while cribriform-negative patients did not benefit from early radical treatment for metastasis prevention. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
From @JAMA_current: Among #medicare Advantage beneficiaries aged 75 years or older with #cancer, a lay health worker–administered telephone assessment reduced acute care use, including 68% lower odds of hospitalization, compared with standard care.
jamanetwork.com/journals/jama/fullarticle/10.1001/jama.20… -
JAMA Oncology
@JAMAOnc
Both combined and progestin-only contraceptives are linked to increased #breastcancer risk, with greater risk observed for progestin-only, particularly desogestrel-containing products. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology reposted
JAMA+ AI
@JAMAplusAI
To mark JAMA+ AI’s first anniversary, editors shared their top article picks.
@JAMAOnc AI Editor Yu Shyr, PhD, chose a study on deep learning–based response prediction for immune checkpoint inhibitor therapy in advanced #nsclc.
🔗: jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… -
JAMA Oncology
@JAMAOnc
From @JAMA_current: After new out-of-pocket caps in 2024, initial and 60-day fill rates increased for #medicare beneficiaries without low-income subsidies, though affordability barriers remain for specialty oral #anticancer drugs.
jamanetwork.com/journals/jama/fullarticle/10.1001/jama.20… -
JAMA Oncology
@JAMAOnc
Sarcomas comprise a heterogeneous group of malignant neoplasms that include genomically simple and genomically complex subtypes. This consensus provides guidelines for efficient, rational use of next-generation sequencing in their clinical management. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Consistent moderate physical activity—about 17 metabolic equivalent task-hours/week over 3 decades—was associated with optimally reduced risk of digestive system cancers in a large cohort study. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
💬 Editorial: Consistent long-term physical activity was linked to optimally reduced risk of digestive system cancers. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Absolute neutrophil count–based eligibility criteria in cancer trials disproportionately exclude Black patients with the Duffy null phenotype, suggesting the need for Duffy status–specific thresholds to improve trial equity. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Immune checkpoint inhibitor–induced #diabetes occurred in 0.52% of patients across 158 National Cancer Institute trials, with higher incidence for combination immunotherapy and lower rates when combined with #chemotherapy. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
A validated risk model accurately predicted 10-year risk of heart failure or cardiomyopathy in women treated for early-stage breast cancer, integrating clinical and treatment variables available at diagnosis. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
The MyLungHealth randomized trial found that digital tools improved eligibility assessment and CT ordering for #lungcancer screening, but gains in scan completion were limited. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Among over 7000 patients with #cancer, higher baseline fatigue before systemic therapy was linked to an increased risk of severe, life-threatening, and fatal adverse events. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Viewpoint: GLP-1 receptor agonists induce weight loss but may lead to pronounced muscle mass reduction, raising concerns for patients with cancer at risk of frailty and decreased physical function. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
During nationwide platinum shortages, #oncologists maintained overall platinum use for nonmetastatic lung cancer and substituted immunotherapy when treating metastatic cases, closely following national guidance. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Viewpoint: The recommendation against hormonal contraception for premenopausal women at risk for or surviving breast cancer while taking tamoxifen is based on limited evidence, underscoring the need for more targeted research. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
The numbers are in.
This year's most popular JAMA Network content spans a range of topics, from #fluoride to #parkinson disease to #glp-1s. What was your favorite article in 2025—and did other readers agree?
🔗 jamanetwork.com/pages/most-viewed-articles?linkId=892306971 -
JAMA Oncology
@JAMAOnc
Ductal carcinoma in situ (DCIS) score profiling after breast-saving surgery enabled selective radiotherapy, allowing half of women with DCIS to safely avoid radiotherapy while maintaining low 5-year in-breast recurrence rates for all risk groups. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Editorial: Cardiac surveillance recommendations after breast cancer treatment remain limited, with evidence suggesting most survivors benefit from primary care focused on prevention and management of traditional cardiovascular risk factors. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Breast cancer risk for pathogenic variant carriers is substantially higher with a first-degree family history, and risk estimates vary by gene, family history, and other factors, guiding personalized screening and prevention decisions. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Head and neck #cancer is the seventh most common cancer worldwide.
This JAMA Review summarizes the epidemiology, clinical presentation, diagnosis, and treatment of head and neck squamous cell carcinomas (#hnscc) of the upper aerodigestive tract.
jamanetwork.com/journals/jama/fullarticle/10.1001/jama.20… -
JAMA Oncology
@JAMAOnc
Immune checkpoint inhibitors are independently linked to increased risk of Stevens-Johnson syndrome and toxic epidermal necrolysis, with additive effects observed when combined with high-risk drugs. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Heart radiation therapy, high-dose anthracyclines, and platinum agents were linked with increased risk of symptomatic valvular heart disease, especially at higher doses and longer follow-up. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
💬 Viewpoint: Nonfinancial conflicts, including relationships and beliefs, can shape #oncology research outcomes, highlighting the need for routine disclosure and management to support scientific credibility. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Viewpoint: Proposed use of credit screening in clinical settings could enable rapid detection of financial risk at cancer diagnosis, with automated analysis guiding early financial counseling and support. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
📢 This Special Communication describes obstacles to sharing data and biospecimens and proposes strategies to enhance access and collaboration.
jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… -
JAMA Oncology
@JAMAOnc
Quadrivalent #hpv vaccination was associated with lower rates of high-grade vulvovaginal lesions, especially among women vaccinated at ages 10 to 16, in a large cohort study.
jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… -
JAMA Oncology
@JAMAOnc
#ai technologies hold potential to enhance acute myeloid leukemia management by improving risk stratification, early detection, and treatment optimization through integration of clinical, morphological, and genetic data.
jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… -
JAMA Oncology
@JAMAOnc
In a pooled analysis of patients from 15 phase 3 trials, the risk of #coloncancer recurrence after surgery and adjuvant #chemotherapy fell below 0.5% by 6 years. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Sarcomas comprise a heterogeneous group of malignant neoplasms that include genomically simple and genomically complex subtypes. This consensus provides guidelines for efficient, rational use of next-generation sequencing in their clinical management. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
#ai-detected tumor-infiltrating lymphocytes in pretreatment metastatic melanoma specimens were associated with response to ICI, improved progression-free survival, and improved overall survival. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
A phase 2 trial demonstrated an isotoxic improvement in #cancer control with prostate-specific membrane antigen positron emission tomography-guided intensification of salvage RT after radical prostatectomy. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
💬 Viewpoint: Effective stroke care for patients with cancer requires rapid interdisciplinary communication, clear documentation of prognosis and goals of care, and urgent application of acute stroke therapies. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
In a JAMA #rct presented at #sabcs25, researchers found risk-based breast cancer screening was as safe as annual screening for detecting advanced cancers but did not reduce breast biopsy rates.
@SABCSSanAntonio
jamanetwork.com/journals/jama/fullarticle/2842903?linkId=… -
JAMA Oncology
@JAMAOnc
Definitive radiotherapy with or without chemotherapy in anterior nasal cavity cancers achieved high rates of long-term organ preservation & favorable local recurrence rates for patients who declined rhinectomy or had unresectable disease. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
In this secondary analysis of the RxPONDER trial, chemoendocrine therapy was associated with greater and more persistent self-reported cognitive impairment than endocrine therapy alone in both pre- and postmenopausal women with #breastcancer. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
💬 Editorial: Cancer-related cognitive impairment frequently affects #breastcancer survivors and may persist for years after treatment, with greater risk among those receiving chemoendocrine therapy.
jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… -
JAMA Oncology
@JAMAOnc
✅ Thinking about submitting your #ash25 research to @JAMA_current, @JAMAOnc, @JAMAPediatrics, @JAMANetworkOpen, or one of our other Network journals?
This video tells you what to expect from the submission and review process. www.youtube.com/watch?linkId=884395615&v=YQhpKdSfc_g -
JAMA Oncology
@JAMAOnc
📖 Olverembatinib After Failure of Tyrosine Kinase Inhibitors, Including Ponatinib or Asciminib: A Phase 1b Randomized Clinical Trial, from @JAMAOnc.
🔗 Free to read online during #ash25. jamanetwork.com/pages/conferences-ash?linkId=884394985 -
JAMA Oncology
@JAMAOnc
📣 Final day of exhibits at #ash25.
📍 Find us at booth 1927 to get recent articles for your trip home and ask about submitting your research presented at the meeting to @JAMA_current, @JAMAOnc, @JAMANetworkOpen, or one of our other JAMA Network journals. -
JAMA Oncology
@JAMAOnc
📚 Supplement your #ash25 schedule with Dasatinib & CAR T-Cell Therapy in Newly Diagnosed Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia: A Nonrandomized Clinical Trial, from @JAMAOnc.
🔗 Free to read online during the meeting. jamanetwork.com/pages/conferences-ash?linkId=884394005 -
JAMA Oncology
@JAMAOnc
Viewpoint: @US_FDA analysis of primary clinical trial data frequently uncovers risks and flaws not apparent in published studies, highlighting the importance for clinicians to consider these regulatory insights in their treatment decisions. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
📣 Exhibits at #ash25 are open.
📍 Find @JAMA_current, @JAMAOnc, and @JAMANetworkOpen at booth 1927.
Get recent articles, find out when you can meet our editors, and ask us about publishing opportunities and submitting your work. -
JAMA Oncology
@JAMAOnc
Meet @JAMAOnc Editorial Board member @chadinabhan at #ash25.
📍 Booth 1927 in the exhibit hall.
📅 Saturday, Dec 6, 11:00 AM - 12:00 PM.
➡️ Stop by to ask questions and talk with him about your research and publishing opportunities with the JAMA Network. -
JAMA Oncology
@JAMAOnc
A 400-mg ribociclib starting dose did not match the efficacy of 600 mg in HR+/ERBB2− advanced breast cancer, but had similar progression-free survival and fewer adverse events. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Attending #ash25?
📚 Check out our page created for attendees. Get recent articles, find out when you can meet our editors, and get information For Authors on JAMA_current, JAMAOnc, JAMAPediatrics, and JAMANetworkOpen. jamanetwork.com/pages/conferences-ash?linkId=884386666 -
JAMA Oncology
@JAMAOnc
This JAMA Oncology Patient Page describes the 3 main types of urinary diversions and care required after surgery to ensure an active and fulfilling life. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
A prediction model incorporating clonal hematopoiesis and other factors identified substantial heterogeneity in the cancer-preventive effect of low-dose aspirin among older adults. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
💬 Editorial: Precision adjuvant therapy for stage III #coloncancer may be enhanced through molecular profiling for ctDNA status and PIK3CA mutation, informing use of celecoxib or aspirin alongside standard treatment. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
ctDNA status may help identify which patients benefit from adjuvant celecoxib, supporting personalized treatment approaches in #coloncancer. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Viewpoint explores the growing complexity of #cancer care and the essential role of #ai-enhanced decision support tools in helping oncologists manage evolving treatment options and maintain high-quality patient care. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Many elevated PSA levels normalize within a year, but consistently high values warrant direct diagnostic evaluation without repeated testing. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Among adolescents and young adults with #cancer, 9.5% of patients with earlier-stage cancer experienced metastatic recurrence within five years, with the highest rates in sarcoma (24.5%) and colorectal cancer (21.8%).
jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… -
JAMA Oncology
@JAMAOnc
Specific oral bacteria and fungi were risk factors for pancreatic cancer development, suggesting the potential use of oral microbiota as noninvasive biomarkers for identifying high-risk individuals.
jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… -
JAMA Oncology
@JAMAOnc
More young people are now being diagnosed with lung cancer than in the past.
This JAMA Oncology Patient Page describes causes, types, and symptoms of lung cancer in people younger than 50 years and how it can be treated.
jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… -
JAMA Oncology
@JAMAOnc
Among adolescents and young adults with #cancer, 9.5% of patients with earlier-stage cancer experienced metastatic recurrence within five years, with the highest rates in sarcoma (24.5%) and colorectal cancer (21.8%).
jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… -
JAMA Oncology
@JAMAOnc
Despite high insurance coverage rates, individuals diagnosed with #cancer in Massachusetts experienced increases in medical debt, with those having bladder and colorectal cancer facing additional increases.
jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… -
JAMA Oncology
@JAMAOnc
Pembrolizumab combined with platinum-based chemotherapy showed a 39.4% response rate and manageable toxicity as a potential first-line treatment for advanced penile squamous cell carcinoma.
jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… -
JAMA Oncology
@JAMAOnc
On December 1 at 10 AM ET, JAMA Editor in Chief Kirsten Bibbins-Domingo, PhD, MD, MAS, will co-chair a public, live-streamed webinar discussing a new @WHO guideline concerning #glp-1 therapy and adults with #obesity.
Register for the webinar: www.who.int/news-room/events/detail/2025/12/01/default-ca… -
JAMA Oncology
@JAMAOnc
Among adolescents and young adults with #cancer, 9.5% of patients with earlier-stage cancer experienced metastatic recurrence within five years, with the highest rates in sarcoma (24.5%) and colorectal cancer (21.8%).
jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… -
JAMA Oncology
@JAMAOnc
In early 2025, the National Cancer Institute terminated 181 extramural grants, totaling more than $640 million in awards. Terminations targeted primarily basic science, general oncology, and early-career investigators.
jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… -
JAMA Oncology
@JAMAOnc
With an estimated 1.8 million deaths annually, primary lung cancer is the leading cause of cancer-related deaths.
This Review discusses the controversies and challenges in the treatment of synchronous oligometastatic NSCLC without an AGA.
jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… -
JAMA Oncology
@JAMAOnc
Phase 2 trial finds lorlatinib yielded a 73% objective response rate and median progression-free survival of 53.6 months in TKI-naive advanced ROS1-positive NSCLC.
jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… -
JAMA Oncology
@JAMAOnc
Patient-reported outcomes, such as higher health status and lower symptom burden, are independently associated with improved overall survival in cancer patients. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
On December 1 at 10 AM ET, JAMA Editor in Chief Kirsten Bibbins-Domingo, PhD, MD, MAS, will co-chair a public, live-streamed webinar discussing a new WHO guideline concerning #glp-1 therapy and adults with #obesity.
Register for the webinar: www.who.int/news-room/events/detail/2025/12/01/default-ca… -
JAMA Oncology
@JAMAOnc
Among adolescents and young adults with #cancer, 9.5% of patients with earlier-stage cancer experienced metastatic recurrence within five years, with the highest rates in sarcoma (24.5%) and colorectal cancer (21.8%). 🧵
jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
JAMA Oncology
@JAMAOnc
💬 Editorial: Metastatic recurrence nearly triples mortality risk in #breastcancer among young adults and increases death risk in sarcoma and colorectal cancer—highlighting the need for earlier detection and novel treatments.
jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
JAMA Oncology
@JAMAOnc
Authors Ann Brunson, MS, and Theresa Keegan, PhD, MS, discuss metastatic recurrence among adolescents and young adults with cancer with @VivekSubbiah, MD.
🎧 Listen now: edhub.ama-assn.org/jn-learning/audio-player/10.1001/jamao… -
JAMA Oncology
@JAMAOnc
A review published in @JAMA_current discusses the epidemiology, diagnosis, treatment, and prognosis of #lungcancer in nonsmoking individuals.
➡️ Watch the video for key takeaways and read the full article: jamanetwork.com/journals/jama/fullarticle/10.1001/jama.20…This media couldn't be displayed. See it on the original post. -
JAMA Oncology
@JAMAOnc
Proton craniospinal irradiation significantly improves survival outcomes compared to involved-field radiotherapy for patients with leptomeningeal metastases from non–small cell lung cancer and breast cancer.
jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… -
JAMA Oncology
@JAMAOnc
Head and neck cancer is the seventh most common cancer worldwide.
This Review provides an overview of EGFR-targeted therapies in HNSCC.
jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… -
JAMA Oncology
@JAMAOnc
Editorial: Comparative efficacy between 400-mg and 600-mg ribociclib doses in hormone receptor–positive breast cancer is clinically minimal, but differences in toxicity are significant. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Four-year NATALEE trial results show ribociclib plus NSAI maintains invasive disease-free survival benefit over NSAI alone in hormone receptor–positive/ERBB2-negative early breast cancer. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
💬 Viewpoint: The badscopal effect following ablative radiotherapy signals not failure but biological reorganization, prompting serial metastasis-directed therapy in selected patients. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
For adults with metastatic HER2-positive #biliarytractcancer, zanidatamab led to longer overall survival and reduced pain, supporting its role as a precision therapy option. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
The IMPACT tool accurately stratifies incidental meningioma patients by progression risk, supporting early intervention for high-risk, monitoring for medium-risk, and safe discharge for low-risk individuals. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
In active surveillance for #prostatecancer, #mri was most reliable for ruling out significant cancer in low PSA density cases but failed to achieve sufficient accuracy in broader populations. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Meta-analysis: Among patients with intermediate-, high-, or very high-risk prostate cancer, the ideal duration of ADT with radiotherapy demonstrated nonlinear benefits, with diminished gains after 12 months and variation in benefit by risk group. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
💬 Viewpoint: #medicaid cuts and work requirements in the 2025 budget law risk reduced access to cancer prevention, delayed diagnoses, later-stage disease at presentation, and caused worse cancer outcomes. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
💬 Viewpoint: Trust in medicine has declined due to the #covid19 pandemic and abundant online health information, highlighting the need for transparent, patient-focused communication. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Among patients with advanced urothelial cancer, upfront enfortumab vedotin dose reduction was linked to a 50% reduction in treatment interruption risk but did not compromise overall survival. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
💬 Viewpoint: #ovariancancer's unique attributes complicate early detection, necessitating personalized risk-based strategies for better prevention and outcomes. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Cross-disciplinary international position statement summarizes the current understanding of CV toxic effects associated with ICI therapy, including strategies for diagnosis, treatment, and potential rechallenge and an outline of relevant knowledge gaps. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Among women under 50, those with the highest ultraprocessed food intake had 45% higher odds of early-onset colorectal conventional adenomas versus those with the lowest intake; no significant association was seen for serrated lesions. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
In a nonrandomized phase 2 trial of adults with advanced dMMR/MSI-H noncolorectal cancers, combined nivolumab/ipilimumab showed an objective response rate of 63% and 6-month progression-free survival rate of 71%. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
💬 Viewpoint: Addressing food insecurity, particularly among #cancer patients, requires systemic policy changes that prioritize sustainable funding and support for large-scale food assistance programs. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
💬 Viewpoint: Oncology is shifting toward personalized, less aggressive treatments for "good-risk" metastatic prostate cancer and similar tumors, prioritizing efficacy and quality of life over overtreatment. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
A 78-year-old man with a history of nonmelanoma skin cancers presented with left-sided upper and lower facial weakness. What is your diagnosis? jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
The JAMA Network invites research submissions on #ai in clinical settings, prioritizing rigorous methodologies and validation for informed medical practice.
🔗 See the full submission criteria: jamanetwork.com/journals/jama/fullarticle/10.1001/jama.20… -
JAMA Oncology
@JAMAOnc
Viewpoint: GLP-1 receptor agonists induce weight loss but may lead to pronounced muscle mass reduction, raising concerns for patients with cancer at risk of frailty and decreased physical function. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Rare pathogenic variants in 16 #cancer predisposition genes were linked to both single and multiple cancer diagnoses, suggesting multigene panel testing could be beneficial. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Semaglutide and tirzepatide prescriptions for obesity have increased among patients with preexisting cancer, with notable variation by cancer type and absence of cancer-specific guidelines. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
AI technologies hold potential to enhance acute myeloid leukemia management by improving risk stratification, early detection, and treatment optimization through integration of clinical, morphological, and genetic data. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Older age in unrelated donors linked to lower survival in allogeneic hematopoietic cell transplant with conventional calcineurin inhibitor-based graft-vs-host disease prophylaxis, but this association is mitigated with posttransplant cyclophosphamide.
jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… -
JAMA Oncology
@JAMAOnc
Consistent moderate physical activity—about 17 metabolic equivalent task-hours/week over 3 decades—was associated with optimally reduced risk of digestive system cancers in a large cohort study. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
While the use of fertility-preserving #hormonaltherapy for early-stage endometrial #cancer has increased, survival outcomes are comparable to #hysterectomy in patients under 40. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
💬 Editorial: Patients with limited nodal disease after neoadjuvant therapy may avoid axillary lymph node dissection by using limited axillary surgery and radiation. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Using the MARI protocol, response-guided axillary treatment in patients with limited nodal disease after primary systemic treatment showed a low risk of axillary recurrence. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Consistent moderate physical activity—about 17 metabolic equivalent task-hours/week over 3 decades—was associated with optimally reduced risk of digestive system cancers in a large cohort study. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
💬 Editorial: Women with #breastcancer and overweight or #obesity have worse outcomes, and while interventions like the BWEL trial show promise in managing weight, more research is needed to enhance treatment options. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
A telephone-based weight loss intervention induced weight loss in patients with #breastcancer with #overweight and #obesity across demographic and treatment factors. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
37% of US adults believe alcohol increases cancer risk, while 53% are unsure, according to a 2024 national survey; misbeliefs persist despite rising alcohol-related cancer rates. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Consistent moderate physical activity—about 17 metabolic equivalent task-hours/week over 3 decades—was associated with optimally reduced risk of digestive system cancers in a large cohort study. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Immune checkpoint inhibitors are independently linked to increased risk of Stevens-Johnson syndrome and toxic epidermal necrolysis, with additive effects observed when combined with high-risk drugs. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Both combined and progestin-only contraceptives are linked to increased breast cancer risk, with greater risk observed for progestin-only, particularly desogestrel-containing products. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
🎧 Listen to authors Yiwen Zhang, PhD, and Edward L. Giovannucci, MD, ScD discuss their article "Consistent Adherence to Physical Activity Guidelines and Digestive System Cancer Risk and Mortality," with Vivek Subbiah, MD. edhub.ama-assn.org/jn-learning/audio-player/10.1001/jamao…
-
JAMA Oncology
@JAMAOnc
💬 Editorial: Consistent long-term physical activity—about 17 metabolic equivalent task-hours/week over 30 years—was linked to optimally reduced risk of digestive system cancers. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Consistent moderate physical activity—about 17 metabolic equivalent task-hours/week over 3 decades—was associated with optimally reduced risk of digestive system cancers in a large cohort study. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Glucagon-like peptide-1 receptor agonists (#glp1s) are associated with a reduced overall #cancer risk in adults with #obesity, lowering the risk for endometrial, ovarian, and meningioma cancers. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
The JAMA Network is committed to providing clinicians & policymakers with the evidence they need to make informed decisions in an evolving technology landscape.
We seek original research on the clinical application of #ai in medicine.
🔗 Learn more: jamanetwork.com/journals/jama/fullarticle/10.1001/jama.20… -
JAMA Oncology
@JAMAOnc
Cisplatin treatment decreased kidney function, with lower baseline eGFR patients at higher CKD risk, and a pretreatment eGFR-based model effectively predicted this risk for clinical use. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Public awareness of #hpv, its vaccine, and its #cancer links is low in the US, especially in the Midwest and South, contributing to suboptimal vaccination rates in these regions. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Sintilimab plus axitinib shows a promising objective response rate and progression-free survival with a manageable safety profile for patients with advanced fumarate hydratase–deficient renal cell carcinoma. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Viewpoint: Proposed use of credit screening in clinical settings could enable rapid detection of financial risk at cancer diagnosis, with automated analysis guiding early financial counseling and support. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Dexrazoxane use in pediatric AML rose from 0.5% to 98.5% between 2010 and 2021, coinciding with a 50% reduction in ICU-level cardiovascular care, supporting rapid adoption of dexrazoxane for cardioprotection with intensive chemotherapy. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Editorial: Cardiac surveillance recommendations after breast cancer treatment remain limited, with evidence suggesting most survivors benefit from primary care focused on prevention and management of traditional cardiovascular risk factors.
jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… -
JAMA Oncology
@JAMAOnc
A validated risk model accurately predicted 10-year risk of heart failure or cardiomyopathy in women treated for early-stage breast cancer, integrating clinical and treatment variables available at diagnosis.
jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… -
JAMA Oncology
@JAMAOnc
Atezolizumab plus bevacizumab optimally balances quality of life preservation and survival benefits for patients with unresectable or advanced hepatocellular carcinoma. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Systematic review: Childhood #cancer survivorship research is concentrated in high-income countries, highlighting a need for broader global studies to ensure equitable outcomes for survivors.
jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… -
JAMA Oncology
@JAMAOnc
ICIs can treat advanced cancers in solid organ transplant recipients, especially cSCC, but overall survival is limited, and mTOR inhibitors with steroids may reduce rejection risk. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
RCT: Bacterial decolonization with mupirocin nasal ointment reduced severe oral mucositis and improves quality of life in nasopharyngeal cancer patients undergoing radiotherapy by decreasing Staphylococcus aureus colonization. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Cribriform morphology predicted 15-year metastasis in #prostatecancer, with radiotherapy plus neoadjuvant ADT reducing this risk, while cribriform-negative patients did not benefit from early radical treatment for metastasis prevention. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Ductal carcinoma in situ (DCIS) score profiling after breast-saving surgery enabled selective radiotherapy, allowing half of women with DCIS to safely avoid radiotherapy while maintaining low 5-year in-breast recurrence rates for all risk groups.
jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… -
JAMA Oncology
@JAMAOnc
Across the JAMA Network, we seek submission of manuscripts describing original research that examines the application of #ai in clinical settings.
🔗 Learn more about submission criteria: jamanetwork.com/journals/jama/fullarticle/10.1001/jama.20… -
JAMA Oncology
@JAMAOnc
#ai-detected tumor-infiltrating lymphocytes in pretreatment metastatic melanoma specimens were associated with response to ICI, improved progression-free survival, and improved overall survival.
jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… -
JAMA Oncology
@JAMAOnc
Sarcomas comprise a heterogeneous group of malignant neoplasms that include genomically simple and genomically complex subtypes.
This consensus provides guidelines for efficient, rational use of next-generation sequencing in their clinical management.
jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… -
JAMA Oncology
@JAMAOnc
From @JAMA_current: #microplastics are increasingly detected in human tissues, with potential links to cognitive, cardiovascular, and inflammatory outcomes.
📌 Learn more: jamanetwork.com/journals/jama/fullarticle/10.1001/jama.20… -
JAMA Oncology
@JAMAOnc
An exploratory analysis published in @JAMAOnc examined the long-term efficacy and safety of adjuvant ribociclib plus a nonsteroidal aromatase inhibitor in patients with hormone receptor–positive, HER2-negative early breast cancer.
Read the full results: jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… -
JAMA Oncology
@JAMAOnc
Absolute neutrophil count–based eligibility criteria in cancer trials disproportionately exclude Black patients with the Duffy null phenotype, suggesting the need for Duffy status–specific thresholds to improve trial equity.
jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… -
JAMA Oncology
@JAMAOnc
Can a lower dose of ribociclib help minimize toxic effects in advanced #breastcancer? A phase 2 clinical trial published in JAMA Oncology provides the latest evidence.
Watch the video and read the full results: jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… -
JAMA Oncology
@JAMAOnc
From @JAMA_current: The importance of oral health may extend to cancer prevention.
New research finds that bacteria and fungi from the mouth may affect pancreatic #cancer risk.
#microbiome
jamanetwork.com/journals/jama/fullarticle/10.1001/jama.20… -
JAMA Oncology
@JAMAOnc
In a case-control study of long-term childhood cancer survivors, heart radiation therapy, high-dose anthracyclines, and platinum agents were linked with increased risk of symptomatic valvular heart disease, especially at higher doses and longer follow-up.
jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… -
JAMA Oncology
@JAMAOnc
Breast cancer risk for pathogenic variant carriers is substantially higher with a first-degree family history, and risk estimates vary by gene, family history, and other factors, guiding personalized screening and prevention decisions.
jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… -
JAMA Oncology
@JAMAOnc
Specific oral bacteria and fungi were risk factors for pancreatic cancer development, suggesting the potential use of oral microbiota as noninvasive biomarkers for identifying high-risk individuals.
jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… -
JAMA Oncology
@JAMAOnc
In a pooled analysis of patients from 15 phase 3 trials, the risk of #coloncancer recurrence after surgery and adjuvant chemotherapy fell below 0.5% by six years.
jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… -
JAMA Oncology
@JAMAOnc
A phase 2 trial demonstrated an isotoxic improvement in #cancer control with prostate-specific membrane antigen positron emission tomography-guided intensification of salvage RT after radical prostatectomy.
jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… -
JAMA Oncology
@JAMAOnc
A 400-mg ribociclib starting dose did not match the efficacy of 600 mg in HR+/ERBB2− advanced breast cancer, but had similar progression-free survival and fewer adverse events. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
A 400-mg ribociclib starting dose did not match the efficacy of 600 mg in HR+/ERBB2− advanced breast cancer, but had similar progression-free survival and fewer adverse events. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Four-year NATALEE trial results show ribociclib plus NSAI maintains invasive disease-free survival benefit over NSAI alone in hormone receptor–positive/ERBB2-negative early breast cancer.
jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… -
JAMA Oncology
@JAMAOnc
More young people are now being diagnosed with lung cancer than in the past.
This JAMA Oncology Patient Page describes causes, types, and symptoms of lung cancer in people younger than 50 years and how it can be treated. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… -
JAMA Oncology
@JAMAOnc
A 400-mg ribociclib starting dose did not match the efficacy of 600 mg in HR+/ERBB2− advanced breast cancer, but had similar progression-free survival and fewer adverse events. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Head and neck cancer is the seventh most common cancer worldwide.
This Review provides an overview of EGFR-targeted therapies in HNSCC.
jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… -
JAMA Oncology
@JAMAOnc
A prediction model incorporating clonal hematopoiesis and other factors identified substantial heterogeneity in the cancer-preventive effect of low-dose aspirin among older adults.
jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… -
JAMA Oncology
@JAMAOnc
Four-year NATALEE trial results show ribociclib plus NSAI maintains invasive disease-free survival benefit over NSAI alone in hormone receptor–positive/ERBB2-negative early breast cancer.
jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… -
JAMA Oncology
@JAMAOnc
Editorial: Comparative efficacy between 400-mg and 600-mg ribociclib doses in hormone receptor–positive breast cancer is clinically minimal, but differences in toxicity are significant. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Four-year NATALEE trial results show ribociclib plus NSAI maintains invasive disease-free survival benefit over NSAI alone in hormone receptor–positive/ERBB2-negative early breast cancer.
jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… -
JAMA Oncology
@JAMAOnc
A 400-mg ribociclib starting dose did not match the efficacy of 600 mg in HR+/ERBB2− advanced breast cancer, but had similar progression-free survival and fewer adverse events. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Viewpoint: FDA analysis of primary clinical trial data frequently uncovers risks and flaws not apparent in published studies, highlighting the importance for clinicians to consider these regulatory insights in their treatment decisions.
jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… -
JAMA Oncology
@JAMAOnc
Many elevated PSA levels normalize within a year, but consistently high values warrant direct diagnostic evaluation without repeated testing.
jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… -
JAMA Oncology
@JAMAOnc
🔊 Listen to Jiyoung Ahn, PhD, of @nyugrossman, discuss with @VivekSubbiah, MD, about whether the oral bacterial and fungal microbiome is associated with the development of pancreatic cancer.
Listen now: edhub.ama-assn.org/jn-learning/audio-player/19004027?link… -
JAMA Oncology
@JAMAOnc
Specific oral bacteria and fungi were risk factors for pancreatic cancer development, suggesting the potential use of oral microbiota as noninvasive biomarkers for identifying high-risk individuals.
jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… -
JAMA Oncology
@JAMAOnc
Pembrolizumab combined with platinum-based chemotherapy showed a 39.4% response rate and manageable toxicity as a potential first-line treatment for advanced penile squamous cell carcinoma.
jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… -
JAMA Oncology
@JAMAOnc
Viewpoint: Recognizing the heterogeneity of small cell lung cancer, efforts are underway to apply precision oncology through molecular subtyping and targeted therapies for tailored treatment. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Viewpoint: Prostate cancer screening is shifting toward a more beneficial and less harmful approach by using MRI-targeted strategies, which reduce unnecessary biopsies and overdiagnosis. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… @IvoSchootsNL
-
JAMA Oncology
@JAMAOnc
Following trastuzumab deruxtecan approval, HER2 IHC 3+ testing across 65,000 solid tumors demonstrates varied prevalence. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Viewpoint: Oncology is shifting toward personalized, less aggressive treatments for "good-risk" metastatic prostate cancer and similar tumors, prioritizing efficacy and quality of life over overtreatment. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Patient-reported outcomes, such as higher health status and lower symptom burden, are independently associated with improved overall survival in cancer patients. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… @RSTHuang
-
JAMA Oncology
@JAMAOnc
Approximately one-third of patients treated on TT 2 protocol and half of those treated on TT 3A protocol were alive at 15 to 20 years post-diagnosis. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… @HadidiSamer @ObadaEAbabneh
-
JAMA Oncology
@JAMAOnc
High-dose aumolertinib is associated with long-term survival benefit for patients with untreated EGFR-variant NSCLC and brain metastases. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Preoperative stereotactic radiation therapy (SRT) for resectable brain metastases was found to be safe and reduced the time to treatment completion compared to postoperative SRT. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… @subhaperni @ca_chung @HTawbi_MD
-
JAMA Oncology
@JAMAOnc
"Caring for fasting oncology patients during Ramadan requires a thoughtful, individualized approach."
This Viewpoint discusses how oncology clinicians can provide culturally sensitive care for Muslim cancer patients fasting during Ramadan.
jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… -
JAMA Oncology
@JAMAOnc
Combining utidelone and bevacizumab may effectively treat ERBB2-negative metastatic breast cancer with brain metastases. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
📌 Most viewed this week from JAMA Oncology: Glucagon-like peptide-1 receptor agonists (#glp1s) are associated with a reduced overall #cancer risk in adults with #obesity, lowering the risk for endometrial, ovarian, and meningioma cancers.
jamanetwork.com/journals/jamaoncology/fullarticle/2837870… -
JAMA Oncology
@JAMAOnc
Viewpoint explores the growing complexity of #cancer care and the essential role of #ai-enhanced decision support tools in helping oncologists manage evolving treatment options and maintain high-quality patient care. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… @samyuktaMD
-
JAMA Oncology
@JAMAOnc
With an estimated 1.8 million deaths annually, primary lung cancer is the leading cause of cancer-related deaths. This Review discusses the controversies and challenges in the treatment of synchronous oligometastatic NSCLC without an AGA. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Proton craniospinal irradiation significantly improves survival outcomes compared to involved-field radiotherapy for patients with leptomeningeal metastases from non–small cell lung cancer and breast cancer. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… @JHGLab @DrBetofMDPhD
-
JAMA Oncology
@JAMAOnc
Early variation in circulating tumor DNA (ctDNA) can predict long-term progression-free and overall survival in patients with dMMR/MSI-H metastatic colorectal cancer treated with immune checkpoint inhibitors. @francesco_sullo jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… @david_tougeron
-
JAMA Oncology
@JAMAOnc
Induction-concurrent chemotherapy does not significantly improve progression-free survival compared with concurrent-adjuvant chemotherapy in high-risk N2–3 nasopharyngeal carcinoma. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Cancer rates among people with HIV have declined for certain types, like non-Hodgkin lymphoma and Kaposi sarcoma, due to improved HIV care, though the risk for other cancers remains largely unchanged. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… @camcanepi
-
JAMA Oncology
@JAMAOnc
Despite high insurance coverage rates, individuals diagnosed with #cancer in Massachusetts experienced increases in medical debt, with those having bladder and colorectal cancer facing additional increases. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… @NishantUppal7
-
JAMA Oncology
@JAMAOnc
Rare pathogenic variants in 16 #cancer predisposition genes were linked to both single and multiple cancer diagnoses, suggesting multigene panel testing could be beneficial. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Viewpoint: Trust in medicine has declined due to the #covid19 pandemic and abundant online health information, highlighting the need for transparent, patient-focused communication. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
While the use of fertility-preserving #hormonaltherapy for early-stage endometrial #cancer has increased, survival outcomes are comparable to #hysterectomy in patients under 40. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… @ElkinElena
-
JAMA Oncology
@JAMAOnc
Editorial: Patients with limited nodal disease after neoadjuvant therapy may avoid axillary lymph node dissection by using limited axillary surgery and radiation. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Using the MARI protocol, response-guided axillary treatment in patients with limited nodal disease after primary systemic treatment showed a low risk of axillary recurrence. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Initiating fecal immunochemical test screening for colorectal cancer at ages 40 to 49 leads to reductions in #colorectalcancer mortality and incidence. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
In childhood cancer survivors, obesity was linked to a higher risk of various subsequent neoplasm types, while increased physical activity was associated with a reduced risk. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… @DrDNFriedman
-
JAMA Oncology
@JAMAOnc
A telephone-based weight loss intervention induced significant weight loss in patients with breast cancer with overweight and obesity across demographic and treatment factors.
jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… -
JAMA Oncology
@JAMAOnc
Most viewed this week from @JAMAOnc:
A deep learning #ai model showed improved accuracy over existing biomarkers in predicting immune checkpoint inhibitor treatment response in advanced non-small cell lung #cancer patients.
jamanetwork.com/journals/jamaoncology/fullarticle/2828578… -
JAMA Oncology
@JAMAOnc
Viewpoint: As palliative care clinicians, we urge the adoption of buprenorphine as a first-line opioid for cancer pain due to its effectiveness and safety profile.
jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… -
JAMA Oncology
@JAMAOnc
A telephone-based weight loss intervention induced significant weight loss in patients with breast cancer with overweight and obesity across demographic and treatment factors. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Most viewed this week from @JAMAOnc:
A deep learning #ai model showed improved accuracy over existing biomarkers in predicting immune checkpoint inhibitor treatment response in advanced non-small cell lung #cancer patients.
jamanetwork.com/journals/jamaoncology/fullarticle/2828578… -
JAMA Oncology
@JAMAOnc
Viewpoint discusses how ovarian cancer screening remains ineffective in reducing mortality, prompting experts to advocate for personalized preventive strategies tailored to individual risk profiles.
jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… -
JAMA Oncology
@JAMAOnc
Study demonstrated cisplatin treatment was followed by a predictable decrease in the estimated glomerular filtration rate (eGFR), placing patients with a lower baseline eGFR at the highest risk of CKD. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Glucagon-like peptide-1 receptor agonists (#glp1s) are associated with a reduced overall cancer risk in adults with obesity, lowering the risk for endometrial, ovarian, & meningioma cancers, while potentially increasing the risk for kidney cancer. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
A telephone-based weight loss intervention induced significant weight loss in patients with breast cancer with overweight and obesity across demographic and treatment factors. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
How many future cancers could result from radiation exposure from annual CT exams?
A study published in @JAMAInternalMed estimated future #cancer risk using the National Cancer Institute’s Radiation Risk Assessment Tool. jamanetwork.com/journals/jamainternalmedicine/fullarticle… -
JAMA Oncology
@JAMAOnc
Viewpoint: A tailored, tiered approach to cancer center accreditation could increase hospital participation by addressing existing barriers and aligning costs with hospital capabilities. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… @alison_baskin
-
JAMA Oncology
@JAMAOnc
Most viewed this week from @JAMAOnc:
A deep learning #ai model showed improved accuracy over existing biomarkers in predicting immune checkpoint inhibitor treatment response in advanced non-small cell lung #cancer patients.
jamanetwork.com/journals/jamaoncology/fullarticle/2828578… -
JAMA Oncology
@JAMAOnc
Many childhood cancer survivors with severe sensorineural hearing loss (SNHL) due to treatments like platinum chemotherapy and radiotherapy are now eligible for cochlear implant candidacy evaluations. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Public awareness of #hpv, its vaccine, and its #cancer links is low in the US, especially in the Midwest and South, contributing to suboptimal vaccination rates in these regions. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… @ashish_deshmuk
-
JAMA Oncology
@JAMAOnc
Editor's Note from @JAMA_current: The MatchMiner #ai tool developed by @DanaFarber aims to enhance cancer trial enrollment. Author Kenneth Kehl joins @JAMAplusAI EIC Roy Perlis to discuss this and more.
jamanetwork.com/journals/jama/fullarticle/10.1001/jama.20… -
JAMA Oncology
@JAMAOnc
From @JAMA_current: Launch prices for self-administered anticancer drugs under Medicare Part D increased between 2010 and 2025, outpacing inflation despite the Inflation Reduction Act.
jamanetwork.com/journals/jama/fullarticle/10.1001/jama.20… -
JAMA Oncology
@JAMAOnc
Systematic review: Childhood #cancer survivorship research is concentrated in high-income countries, highlighting a need for broader global studies to ensure equitable outcomes for survivors. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… @nbhattmd @venkymd
-
JAMA Oncology
@JAMAOnc
Most viewed this week from @JAMAOnc:
A deep learning #ai model showed improved accuracy over existing biomarkers in predicting immune checkpoint inhibitor treatment response in advanced non-small cell lung #cancer patients.
jamanetwork.com/journals/jamaoncology/fullarticle/2828578… -
JAMA Oncology
@JAMAOnc
Sintilimab plus axitinib shows a promising objective response rate and progression-free survival with a manageable safety profile for patients with advanced fumarate hydratase–deficient renal cell carcinoma. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Atezolizumab plus bevacizumab optimally balances quality of life preservation and survival benefits for patients with unresectable or advanced hepatocellular carcinoma. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Acupuncture reduces nocturia episodes in prostate cancer survivors compared to usual care, with improvements in urinary function and fewer adverse events. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… @JunMaoMD
-
JAMA Oncology
@JAMAOnc
Only 40.6% of US adults recognize the link between alcohol and cancer, according to this population-based study. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Most viewed this week from @JAMAOnc:
A deep learning #ai model showed improved accuracy over existing biomarkers in predicting immune checkpoint inhibitor treatment response in advanced non-small cell lung #cancer patients.
jamanetwork.com/journals/jamaoncology/fullarticle/2828578… -
JAMA Oncology
@JAMAOnc
RET+ NSCLC tumors commonly express MET and TROP2, with MET expression higher than in RET-wild-type controls. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… @Al3ssandroRusso
-
JAMA Oncology
@JAMAOnc
Viewpoint: The rise in early-onset cancers in individuals under 50 may be explained by accelerated biological aging, with aging and cancer sharing common mechanisms.
jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… -
JAMA Oncology
@JAMAOnc
Transgender and gender-diverse patients with breast cancer receive less endocrine therapy and have lower 5-year overall survival compared to cisgender patients. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… @ChandlerCortina @KelleyChanMD
-
JAMA Oncology
@JAMAOnc
Viewpoint: Addressing food insecurity, particularly among #cancer patients, requires systemic policy changes that prioritize sustainable funding and support for large-scale food assistance programs. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Following a diet rich in vegetables, fruits, and whole grains may improve survival in cancer survivors.
Watch JAMA Oncology Editor in Chief Nora Disis discuss 2 studies that examine the impact of lifestyle behaviors on #cancer survivorship. 🧵This media couldn't be displayed. See it on the original post.
JAMA Oncology
@JAMAOnc
Read the Original Investigation “Association of Survival With Adherence to the American Cancer Society Nutrition and Physical Activity Guidelines for Cancer Survivors After Colon Cancer Diagnosis.” jamanetwork.com/journals/jamaoncology/fullarticle/2678094…
JAMA Oncology
@JAMAOnc
Read the Brief Report “Adherence to American Cancer Society Nutrition and Physical Activity Guidelines Among Cancer Survivors.” jamanetwork.com/journals/jamaoncology/fullarticle/2817661…
-
JAMA Oncology
@JAMAOnc
Most viewed this week from @JAMAOnc:
A deep learning #ai model showed improved accuracy over existing biomarkers in predicting immune checkpoint inhibitor treatment response in advanced non-small cell lung #cancer patients.
jamanetwork.com/journals/jamaoncology/fullarticle/2828578… -
JAMA Oncology
@JAMAOnc
A 78-year-old man with a history of nonmelanoma skin cancers presented with left-sided upper and lower facial weakness. What is your diagnosis? jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
RCT: Bacterial decolonization with mupirocin nasal ointment reduced severe oral mucositis and improves quality of life in nasopharyngeal cancer patients undergoing radiotherapy by decreasing Staphylococcus aureus colonization. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
The 2021 USPSTF guidelines on lung cancer screening were associated with increased LCS uptake overall, even as cancer screenings declined during the #covid19 pandemic.
jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
@colazagasti @GlopesMd @latinamd -
JAMA Oncology
@JAMAOnc
For cancer survivors, a sedentary lifestyle may be associated with a higher risk of all-cause and cancer-specific mortality. JAMA Oncology Editor in Chief Mary L. (Nora) Disis, MD, explains the clinical impact of exercise.
JAMA Oncology
@JAMAOnc
Read the JAMA Oncology article featured in the video “Association of Daily Sitting Time and Leisure-Time Physical Activity With Survival Among US Cancer Survivors.” jamanetwork.com/journals/jamaoncology/fullarticle/2787951…
JAMA Oncology
@JAMAOnc
Read the JAMA Oncology article featured in the video “Effectiveness of Aerobic Exercise and Tai Chi Interventions on Sleep Quality in Patients With Advanced Lung Cancer.” jamanetwork.com/journals/jamaoncology/fullarticle/2812767…
-
JAMA Oncology
@JAMAOnc
Nearly half of patients referred for CAR-T therapy at an academic center did not receive it, influenced by factors like rapid disease progression, lack of appropriate therapies, racial disparities, and logistical challenges. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… @RShouval
-
JAMA Oncology
@JAMAOnc
Scheduled lorazepam, alone or combined with haloperidol, more effectively reduced agitation and restlessness in palliative care patients with advanced cancer and delirium than haloperidol or placebo. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… @drdavidhui
-
JAMA Oncology
@JAMAOnc
Viewpoint discusses how "skimming the median" can exaggerate survival gains in clinical trials, underscoring the need to critically evaluate Kaplan-Meier curves alongside hazard ratios. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Grade group 1 prostate cancer detected on biopsy is associated with intermediate or high-risk disease, leading to heterogeneous long-term outcomes, adverse pathology, and increased prostate cancer-specific mortality, jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Scheduled lorazepam, alone or combined with haloperidol, more effectively reduced agitation and restlessness in palliative care patients with advanced cancer and delirium than haloperidol or placebo. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… @drdavidhui
-
JAMA Oncology
@JAMAOnc
Tibremciclib plus fulvestrant was associated with statistically significant and clinically meaningful improvements in progression-free survival compared with placebo plus fulvestrant. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Viewpoint: To meet the escalating #cancer care demands in the US, efficiency improvements and health system reforms are crucial to prevent impacts on patient care and clinician burnout. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Scheduled lorazepam, alone or combined with haloperidol, more effectively reduced agitation and restlessness in palliative care patients with advanced cancer and delirium than haloperidol or placebo. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… @drdavidhui
JAMA Oncology
@JAMAOnc
🎙️In this podcast episode, JAMA Oncology authors David Hui, MD, and Eduardo Bruera, MD, discuss "Proportional Sedation for Persistent Agitated Delirium in Palliative Care," with host @VivekSubbiah, MD.
➡️Listen now on @AMAEdHub: edhub.ama-assn.org/jn-learning/audio-player/10.1001/jamao… -
JAMA Oncology reposted
ilyas sahin, MD
@ilyassahinMD
Two new @JAMAOnc papers highlight the impact of COVID-19 in cancer patients.
-COVID-19 boosters reduced hospitalization by ~30% and ICU admission by ~36%.
-Lymphoma and lung cancer patients had the highest COVID-related death risk. Chemotherapy and prior cardiovascular events increased hospitalization risk, but prior vaccination cut it by 50%.
-COVID-19 also led to treatment disruptions in many patients!!!
Findings support that vaccination should be part of routine cancer care, especially for high-risk patients‼️ -
JAMA Oncology reposted
BMJ Oncology
@BMJOncology
In a retrospective cohort study among persons with cancer in the US, COVID-19 boosters reduced hospitalizations by 29%.
@JAMAOnc
jamanetwork.com/journals/jamaoncology/fullarticle/2836491 -
JAMA Oncology reposted
Yale Cancer Center
@YaleCancer
In this @JAMAOnc editorial, @AlisaRybkin et al. explain how distant relapse has become the key challenge as #radiotherapy improves locoregional control in locally advanced nasopharyngeal carcinoma #lanpc. Optimizing systemic therapy + ⬇️ toxicity is critical to improve outcomes.
jamanetwork.com/journals/jamaoncology/article-abstract/28…
@SmilowCancer @HenryParkMD @AartiBhatiaMD -
JAMA Oncology reposted
AMA Ed Hub™
@AMAEdHub
A woman in her 50s presented with a history of abdominal pain, weight loss and a large palpable fixed abdominal mass. Biopsies and molecular testing found a mismatch repair–deficient transverse colon adenocarcinoma. What is your diagnosis? @JAMAOnc amaedhub.org/4lYwDeW
-
JAMA Oncology
@JAMAOnc
Revised reference intervals for serum free light chains reduced false-positive rates for LC-MGUS diagnosis by 82%. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… @thorirlong @runolfpa
-
JAMA Oncology
@JAMAOnc
Digital breast tomosynthesis improves specificity and reduces recall and advanced cancer rates compared to digital mammography in women with a family history of breast cancer. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… @JanieMLee1
-
JAMA Oncology
@JAMAOnc
Most viewed this week from @JAMAOnc:
Total neoadjuvant therapy (TNT) for stage II/III rectal cancer, despite variations in regimen choice, showed efficacy outcomes in routine clinical practice consistent with clinical trials.
jamanetwork.com/journals/jamaoncology/fullarticle/2835958… -
JAMA Oncology
@JAMAOnc
Neoadjuvant PD-1/PD-L1 blockade combined with chemotherapy improved pathological response rates and surgical resectability in patients with T4 and/or N2-N3 stage III NSCLC. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… @EdoardoGarbo
-
JAMA Oncology
@JAMAOnc
Viewpoint: The rise of social media and #ai in oncology has transformed scientific communication but also fuels bias, misinterpretation, and financial conflicts of interest. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… @oncoblogger
-
JAMA Oncology
@JAMAOnc
From @JAMA_current: Diverticulitis, an inflammatory condition of diverticula, affects roughly 180 per 100 000 people annually in the US.
This Review summarizes current evidence and treatment of diverticulitis.
jamanetwork.com/journals/jama/fullarticle/10.1001/jama.20… beccabrownmd -
JAMA Oncology
@JAMAOnc
Postoperative stereotactic body radiotherapy for prostate cancer was well-tolerated with similar urinary and bowel patient-reported outcomes over two years compared to conventional radiotherapy. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Most viewed this week from @JAMAOnc:
Total neoadjuvant therapy (TNT) for stage II/III rectal cancer, despite variations in regimen choice, showed efficacy outcomes in routine clinical practice consistent with clinical trials.
jamanetwork.com/journals/jamaoncology/fullarticle/2835958… -
JAMA Oncology
@JAMAOnc
From @JAMA_current: Prostate cancer is the second most common cancer in older men worldwide, with 3.4 million cases in the US in 2021.
This JAMA Patient Page describes prostate cancer symptoms, screening, diagnosis, and treatment.
jamanetwork.com/journals/jama/fullarticle/10.1001/jama.20… -
JAMA Oncology
@JAMAOnc
A risk-reducing mastectomy is cost-effective for women aged 30 to 55 with a lifetime breast cancer risk of 35% or higher, regardless of carrying BRCA1, BRCA2, or PALB2 variants. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
After induction chemotherapy for locoregionally advanced nasopharyngeal carcinoma, radiotherapy plus adjuvant chemotherapy was noninferior to concurrent chemoradiotherapy with reduced severe acute toxicities during radiotherapy. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
While phase 3 oncology trials frequently report success based on alternative endpoints, actual enhancements in overall survival and quality of life are uncommon. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… @AlexSherryMD @oncology_bg @PavlosMsaouel @ebludmir
-
JAMA Oncology
@JAMAOnc
From @JAMA_current: Approximately 21 000 women are diagnosed with ovarian cancer annually in the US.
This Review summarizes the diagnosis and management of high-grade serous ovarian cancer.
jamanetwork.com/journals/jama/fullarticle/10.1001/jama.20… -
JAMA Oncology
@JAMAOnc
Combining immune checkpoint inhibitors with chemotherapy in the first line of treatment for older adults with non–small cell lung cancer can delay mortality but increases the risk of severe adverse events. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… @josephcmurray
-
JAMA Oncology
@JAMAOnc
Most viewed this week from @JAMAOnc:
Total neoadjuvant therapy (TNT) for stage II/III rectal cancer, despite variations in regimen choice, showed efficacy outcomes in routine clinical practice consistent with clinical trials.
jamanetwork.com/journals/jamaoncology/fullarticle/2835958… -
JAMA Oncology
@JAMAOnc
Among two U.S prostate cancer registries, the proportion of patients undergoing prostatectomy for indolent cancer dropped over five-fold from 2010 to 2024. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… @monda_steven @4rnav @MUSICurology @wandering_gu
-
JAMA Oncology
@JAMAOnc
Viewpoint discusses how oncology drug development is shifting from immunotherapy to targeted therapies like antibody-drug conjugates and radioligand therapy.
jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… -
JAMA Oncology
@JAMAOnc
Review: Research advancements in acute lymphoblastic leukemia (ALL) have led to improved outcomes through the use of targeted therapies and immunotherapies, reducing the reliance on prolonged chemotherapy. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
From @JAMA_current: Early-onset gastrointestinal cancers are among the largest subset of early-onset cancers globally.
This JAMA Review summarizes current evidence on early-onset gastrointestinal cancers.
jamanetwork.com/journals/jama/fullarticle/10.1001/jama.20…
@KimmieNgMD @DanaFarber -
JAMA Oncology
@JAMAOnc
A woman in her 50s with a history of hemochromatosis, psoriasis, and type 2 diabetes presented with a 3-month history of abdominal pain, weight loss, and a large palpable fixed abdominal mass. What is your diagnosis? jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Most viewed this week from @JAMAOnc:
Total neoadjuvant therapy (TNT) for stage II/III rectal cancer, despite variations in regimen choice, showed efficacy outcomes in routine clinical practice consistent with clinical trials.
jamanetwork.com/journals/jamaoncology/fullarticle/2835958… -
JAMA Oncology
@JAMAOnc
Cell-free DNA (cfDNA) testing could improve colorectal cancer detection and reduce mortality in Canada, but it requires higher participation rates to be effective compared to current screening methods. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… @jonathanloree
-
JAMA Oncology
@JAMAOnc
In the post–COVID-19 period, there was a reduction in annual breast cancer surveillance imaging for early-stage breast cancer patients, though recurrence rates remained consistent with pre–COVID-19 levels. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Among cancer patients, receiving #covid19 booster vaccines led to a 29-30% reduction in hospitalizations and ICU admissions. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Among cancer patients, #covid19 poses heightened risks particularly for those with hematologic malignancies and underlying health issues, while vaccination reduces hospitalization chances. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… @aakonc
-
JAMA Oncology
@JAMAOnc
Although broad genomic profiling use in newly diagnosed metastatic cancer patients increased from 2020 to 2022, it remained below 50% overall. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
The use of certain oncology medications decreased after negative confirmatory trials and @US_FDA withdrawal of accelerated approval indications. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… @amarkelkar @bnrome
-
JAMA Oncology
@JAMAOnc
Most viewed this week from @JAMAOnc:
Nivolumab and ipilimumab were effective in treating advanced gynecological clear cell cancers, with a 54% response rate and 58% six-month progression-free survival.
jamanetwork.com/journals/jamaoncology/fullarticle/2835771… -
JAMA Oncology
@JAMAOnc
Despite the value of genomic assays in personalizing breast cancer treatment, this review found that they do not fully address racial and ethnic disparities in outcomes. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… @YAbdouMD
-
JAMA Oncology
@JAMAOnc
The management of brain metastases in EGFR-variant and ALK-positive NSCLC patients remains uncertain, with evidence suggesting that upfront stereotactic radiosurgery (SRS) offers better local control and delays CNS progression. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… @Pike_lab
-
JAMA Oncology
@JAMAOnc
Viewpoint: Cancer patients frequently face costly dental complications, particularly in head and neck cancers, requiring improved insurance coverage to reduce financial burdens.
jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… -
JAMA Oncology
@JAMAOnc
Most viewed this week from @JAMAOnc:
Nivolumab and ipilimumab were effective in treating advanced gynecological clear cell cancers, with a 54% response rate and 58% six-month progression-free survival.
jamanetwork.com/journals/jamaoncology/fullarticle/2835771… -
JAMA Oncology
@JAMAOnc
Total neoadjuvant therapy for stage II/III rectal cancer, despite variations in regimen choice, showed efficacy outcomes in routine clinical practice consistent with clinical trials. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
RCT: Adjuvant therapy combining chemoradiation and camrelizumab improves overall and recurrence-free survival in patients with resectable extrahepatic cholangiocarcinoma and gallbladder cancer. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
The growing cancer burden may be met by efforts to strengthen the clinical workforce, improve gender equity, increase healthcare resource allocation, and promote universal healthcare coverage. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… @EChrisDee @erin_feliciano @iyengarpuneeth
-
JAMA Oncology
@JAMAOnc
This cohort study suggests that chromosomal alterations should be included in the WHO grading criteria for meningiomas, as they are associated with worse outcomes and can refine the current classification system. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… @DrAMansouri @afgao
-
JAMA Oncology
@JAMAOnc
Nivolumab and ipilimumab were effective in treating advanced gynecological clear cell cancers, with a 54% response rate and 58% six-month progression-free survival.
jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… -
JAMA Oncology
@JAMAOnc
Viewpoint: Despite advances in data reconstruction and sharing initiatives, limited access to individual patient data from cancer trials hinders research progress.
jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… @l_trinquart @martinstockler -
JAMA Oncology
@JAMAOnc
"If funding is diminished, it will be catastrophic to millions of patients and families who will experience the devastation of cancer in the coming years."
Richard J Boxer discusses the effect of decreased funding for cancer research in the US.
jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… -
JAMA Oncology
@JAMAOnc
A woman in her 40s with well-differentiated neuroendocrine tumor of the pancreas with liver metastases undergoing treatment with oral cabozantinib presented to a routine oncology appointment with tongue lesions for 1 week.
What is your diagnosis? jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… -
JAMA Oncology
@JAMAOnc
Nivolumab and ipilimumab were effective in treating advanced gynecological clear cell cancers, with a 54% response rate and 58% six-month progression-free survival.
jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… -
JAMA Oncology
@JAMAOnc
Viewpoint: Effective cancer control must include integrated strategies like updated warning labels and public education to address the cancer risk associated with alcohol consumption. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Combining immune checkpoint inhibitors with targeted therapies, particularly tyrosine kinase inhibitors, showed promising efficacy in treating various subtypes of metastatic non–clear cell renal cell carcinoma. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
MoST-CIRCUIT trial: Nivolumab and ipilimumab were effective in treating advanced #gynecological clear cell #cancers, with a 54% response rate and 58% six-month progression-free survival.
jamanetwork.com/journals/jamaoncology/fullarticle/2835771… -
JAMA Oncology
@JAMAOnc
MoST-CIRCUIT trial: Nivolumab and ipilimumab were effective in treating advanced gynecological clear cell cancers, with a 54% response rate and 58% six-month progression-free survival. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Adding atezolizumab to trastuzumab and XELOX chemotherapy increased the pathological complete response rate in Chinese patients with locally advanced ERBB2-positive gastric or gastroesophageal junction cancer. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Ablative radiation therapy effectively controlled tumors and provided favorable 2-year survival rates in patients with resectable pancreatic cancer who could not undergo surgery. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… @EileenMOReilly @JohnCuaron
-
JAMA Oncology
@JAMAOnc
Most viewed this week from @JAMAOnc:
ICIs can treat advanced cancers in solid organ transplant recipients, especially cSCC, but overall survival is limited, and mTOR inhibitors with steroids may reduce rejection risk.
jamanetwork.com/journals/jamaoncology/fullarticle/2835689… -
JAMA Oncology
@JAMAOnc
This year, JAMA Oncology celebrates 10 years of publication. Editor in Chief @DrNDisis reflects on some of the most notable articles from the past decade and what is to come for the journal. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Viewpoint: Recognizing the heterogeneity of small cell lung cancer, efforts are underway to apply precision oncology through molecular subtyping and targeted therapies for tailored treatment. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Following trastuzumab deruxtecan approval, HER2 IHC 3+ testing across 65,000 solid tumors demonstrates varied prevalence. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Most viewed this week from @JAMAOnc:
ICIs can treat advanced cancers in solid organ transplant recipients, especially cSCC, but overall survival is limited, and mTOR inhibitors with steroids may reduce rejection risk.
jamanetwork.com/journals/jamaoncology/fullarticle/2835689… -
JAMA Oncology
@JAMAOnc
Viewpoint: The 21st Century Cures Act, which mandates real-time patient access to health data, aims to empower patients but has led to confusion, anxiety, and increased administrative burdens for clinicians. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Combining utidelone and bevacizumab may effectively treat ERBB2-negative metastatic breast cancer with brain metastases. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
High-dose aumolertinib is associated with long-term survival benefit for patients with untreated EGFR-variant NSCLC and brain metastases. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Prophylactic IV magnesium administration was associated with a lower risk of cisplatin-associated acute kidney injury (CP-AKI) in patients with cancer undergoing cisplatin chemotherapy. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
AI and natural language processing (NLP) can effectively analyze large datasets of patient messages to generate meaningful and novel research topics in cancer care. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… @caswell_jin
-
JAMA Oncology
@JAMAOnc
Combining dasatinib with CAR T-cell therapy in newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia patients resulted in high rates of complete molecular remission. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Immune checkpoint inhibitors can improve survival in solid organ transplant recipients with advanced cancers, but survival rates remain limited.
#tsanzconf @TSANZ_txsoc
jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… -
JAMA Oncology
@JAMAOnc
Viewpoint: Cabozantinib capsules are more cost-effective than tablets for treating various cancers, and adopting capsule-based dosing strategies could reduce costs while maintaining efficacy. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Middle East and North African countries are underrepresented in oncology clinical trials, with higher participation in observational, late-phase, and industry-funded trials, and greater representation in countries with higher GDP. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Viewpoint: Prostate cancer screening is shifting toward a more beneficial and less harmful approach by using MRI-targeted strategies, which reduce unnecessary biopsies and overdiagnosis. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… @IvoSchootsNL
-
JAMA Oncology
@JAMAOnc
Early variation in circulating tumor DNA (ctDNA) can predict long-term progression-free and overall survival in patients with dMMR/MSI-H metastatic colorectal cancer treated with immune checkpoint inhibitors. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… @david_tougeron
-
JAMA Oncology
@JAMAOnc
Induction-concurrent chemotherapy does not significantly improve progression-free survival compared with concurrent-adjuvant chemotherapy in high-risk N2–3 nasopharyngeal carcinoma. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Preoperative stereotactic radiation therapy (SRT) for resectable brain metastases was found to be safe and reduced the time to treatment completion compared to postoperative SRT. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… @subhaperni @ca_chung @HTawbi_MD
-
JAMA Oncology
@JAMAOnc
"Caring for fasting oncology patients during Ramadan requires a thoughtful, individualized approach."
This Viewpoint discusses how oncology clinicians can provide culturally sensitive care for Muslim cancer patients fasting during Ramadan.
jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… -
JAMA Oncology
@JAMAOnc
Cancer rates among people with HIV have declined for certain types, like non-Hodgkin lymphoma and Kaposi sarcoma, due to improved HIV care, though the risk for other cancers remains largely unchanged. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Initiating fecal immunochemical test screening for colorectal cancer at ages 40 to 49 leads to reductions in colorectal cancer mortality and incidence. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Most viewed this week from @JAMAOnc:
While phase 3 oncology trials frequently report success based on alternative endpoints, actual enhancements in overall survival and quality of life are uncommon.
jamanetwork.com/journals/jamaoncology/fullarticle/2834980… -
JAMA Oncology
@JAMAOnc
Viewpoint: As palliative care clinicians, we urge the adoption of buprenorphine as a first-line opioid for cancer pain due to its effectiveness and safety profile.
jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… -
JAMA Oncology
@JAMAOnc
From @JAMAInternalMed: Mailed self-collection was effective for increasing #cervicalcancer screening participation among never- and under-screened women in a safety net health setting.
jamanetwork.com/journals/jamainternalmedicine/fullarticle… -
JAMA Oncology
@JAMAOnc
Approximately one-third of patients treated on TT 2 protocol and half of those treated on TT 3A protocol were alive at 15 to 20 years post-diagnosis.
jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… -
JAMA Oncology
@JAMAOnc
Most viewed this week from @JAMAOnc:
While phase 3 oncology trials frequently report success based on alternative endpoints, actual enhancements in overall survival and quality of life are uncommon.
jamanetwork.com/journals/jamaoncology/fullarticle/2834980… -
JAMA Oncology
@JAMAOnc
In childhood cancer survivors, obesity was linked to a higher risk of various subsequent neoplasm types, while increased physical activity was associated with a reduced risk.
jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… -
JAMA Oncology
@JAMAOnc
Survivors of childhood cancer undergo considerable accelerated aging in terms of early onset and excess risk of chronic health conditions.
jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… -
JAMA Oncology
@JAMAOnc
For select breast cancer patients with complete response to neoadjuvant systemic therapy, radiotherapy alone without breast surgery may be feasible, as no tumor recurrences were observed at 5-year follow-up. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology reposted
James Wu | 吴简凡 MD
@JamesFanWu
Some of the best parts of #asco25 is the opportunity to meet in person your research collaborators from around the world!!
Check one of our groups’ most recent publications on “National Cancer System Characteristics and Global Pan-Cancer Outcomes: jamanetwork.com/journals/jamaoncology/article-abstract/28… -
JAMA Oncology
@JAMAOnc
A study of 1.6 million US cancer patients in 2023 found 47.3% had a smoking history, with 14.7% currently smoking at diagnosis. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology reposted
JAMA
@JAMA_current
A cell-free DNA blood test could be an option for patients who repeatedly decline colonoscopy or stool testing for #colorectalcancer screening. #asco25
Read the new JAMA Original Investigation to learn more. jamanetwork.com/journals/jama/fullarticle/2834891?guestAc… -
JAMA Oncology
@JAMAOnc
Interval breast cancer (IntCa) rates remain high despite mammographic screening, highlighting the need for personalized screening based on risk factors like high breast density, hormone replacement therapy, and family history. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
📢 Calling all #asco25 attendees!
Stay up to date with everything JAMA Oncology—follow us on Bluesky.
➡️ bsky.app/profile/jamaoncology.bsky.social?linkId=827316920 -
JAMA Oncology
@JAMAOnc
JAMA Oncology is now on Bluesky! 🦋
Follow us there for the latest original research, opinions, and reviews that advance the science of oncology and improve the clinical care of patients with cancer.
➡️ bsky.app/profile/did:plc:rj6cle4uinetvpabgdddcemo?linkId=… -
JAMA Oncology
@JAMAOnc
Revised reference intervals for serum free light chains reduced false-positive rates for LC-MGUS diagnosis by 82%. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Most viewed this week from @JAMAOnc:
Viewpoint discusses how "skimming the median" can exaggerate survival gains in clinical trials, underscoring the need to critically evaluate Kaplan-Meier curves alongside hazard ratios.
jamanetwork.com/journals/jamaoncology/fullarticle/2834385… -
JAMA Oncology
@JAMAOnc
A 70-year-old man with a history of hypertension and chronic migraine presented with 10 months of progressive generalized muscle weakness and stiffness.
Take the Clinical Challenge. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… -
JAMA Oncology
@JAMAOnc
Phase 3 oncology RCTs often report positive results based on alternative end points, but actual improvements in overall survival or quality of life are rare, highlighting need to prioritize these outcomes in future research & regulatory processes. #asco25 jamanetwork.com/journals/jamaoncology/fullarticle/2834980…
JAMA Oncology
@JAMAOnc
Editor's Note: The Role of Meta-Epidemiology in Oncology Research—Bridging Evidence and Practice #asco25 jamanetwork.com/journals/jamaoncology/fullarticle/2834981…
-
JAMA Oncology
@JAMAOnc
Viewpoint: The rise in early-onset cancers in individuals under 50 may be explained by accelerated biological aging, with aging and cancer sharing common mechanisms. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Revised reference intervals for serum free light chains reduced false-positive rates for LC-MGUS diagnosis by 82%. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Only 40.6% of US adults recognize the link between alcohol and cancer, according to this population-based study. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Most viewed this week from @JAMAOnc:
Viewpoint discusses how "skimming the median" can exaggerate survival gains in clinical trials, underscoring the need to critically evaluate Kaplan-Meier curves alongside hazard ratios.
jamanetwork.com/journals/jamaoncology/fullarticle/2834385… -
JAMA Oncology
@JAMAOnc
RET+ NSCLC tumors commonly express MET and TROP2, with MET expression higher than in RET-wild-type controls. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Revised reference intervals for serum free light chains reduced false-positive rates for LC-MGUS diagnosis by 82%. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
This review evaluates different strategies for treating patients with advanced kidney cancer previously exposed to immunotherapy. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… @paulosiqamaral
-
JAMA Oncology
@JAMAOnc
Narrative review outlines the historical evolution of the COG Long-Term Follow-Up Guidelines for Survivors of Childhood, Adolescent, and Young Adult Cancers, current methods guiding their development, & key recommendations from version 6.0. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Most viewed this week from @JAMAOnc:
Neoadjuvant PD-1/PD-L1 blockade combined with chemotherapy improved pathological response rates and surgical resectability in patients with T4 and/or N2-N3 stage III NSCLC.
jamanetwork.com/journals/jamaoncology/fullarticle/2834387… -
JAMA Oncology
@JAMAOnc
Despite the effectiveness of CAR-T therapy for various blood cancers, its adoption is limited in the US due to infrastructure challenges and restrictive insurance policies. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… @samyuktaMD
-
JAMA Oncology
@JAMAOnc
Viewpoint discusses how "skimming the median" can exaggerate survival gains in clinical trials, underscoring the need to critically evaluate Kaplan-Meier curves alongside hazard ratios. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
A woman in her 50s with a history of hemochromatosis, psoriasis, and type 2 diabetes presented with a 3-month history of abdominal pain, weight loss, and a large palpable fixed abdominal mass. What is your diagnosis? jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Viewpoint discusses how oncology drug development is shifting from immunotherapy to targeted therapies like antibody-drug conjugates and radioligand therapy. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Transgender and gender-diverse patients with breast cancer receive less endocrine therapy and have lower 5-year overall survival compared to cisgender patients. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Most viewed this week from @JAMAOnc:
Neoadjuvant PD-1/PD-L1 blockade combined with chemotherapy improved pathological response rates and surgical resectability in patients with T4 and/or N2-N3 stage III NSCLC.
jamanetwork.com/journals/jamaoncology/fullarticle/2834387… -
JAMA Oncology
@JAMAOnc
Digital breast tomosynthesis improves specificity and reduces recall and advanced cancer rates compared to digital mammography in women with a family history of breast cancer. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Neoadjuvant PD-1/PD-L1 blockade combined with chemotherapy improved pathological response rates and surgical resectability in patients with T4 and/or N2-N3 stage III NSCLC.
jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… -
JAMA Oncology
@JAMAOnc
Neoadjuvant nivolumab + chemotherapy followed by response-stratified chemoradiation in stage IVa/b nonvirally mediated head & neck cancer showed favorable survival & less toxic effects.
jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… -
JAMA Oncology
@JAMAOnc
Adding chemotherapy to radiotherapy was not associated with improved overall survival for patients with intermediate-risk cervical cancer. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Most viewed this week from @JAMAOnc:
Combining immune checkpoint inhibitors with chemotherapy in the first line of treatment for older adults with non–small cell lung cancer can delay mortality but increases the risk of severe adverse events.
jamanetwork.com/journals/jamaoncology/fullarticle/2833552… -
JAMA Oncology
@JAMAOnc
PSA level should be assessed for at least 3 months after radical prostatectomy to minimize overtreatment, and a higher persistent PSA level was associated with a worse prognosis.
jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… -
JAMA Oncology
@JAMAOnc
Viewpoint: The FDA approved sotorasib for non-small cell lung cancer with the KRASG12C mutation under the accelerated approval program in 2021, but concerns remain about the consistency of confirmatory trials and appropriate dosing. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
In this Editorial JAMA Oncology Editor in Chief Mary L. (Nora) Disis discusses the journals impactful publications in 2024, while thanking contributors and highlighting the journal's high readership and rigorous review process. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Most viewed this week from @JAMAOnc:
Combining immune checkpoint inhibitors with chemotherapy in the first line of treatment for older adults with non–small cell lung cancer can delay mortality but increases the risk of severe adverse events.
jamanetwork.com/journals/jamaoncology/fullarticle/2833552… -
JAMA Oncology reposted
JAMA+ AI
@JAMAplusAI
From @JAMAOnc: AI and natural language processing (NLP) can effectively analyze large datasets of patient messages to generate meaningful and novel research topics in cancer care.
jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… -
JAMA Oncology
@JAMAOnc
Nearly half of the patients referred for CAR-T therapy at an academic center did not receive it, with contributing factors including rapid disease progression, lack of suitable therapies, racial disparities, and logistical challenges. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… @RShouval
-
JAMA Oncology
@JAMAOnc
Postoperative stereotactic body radiotherapy for prostate cancer was well-tolerated with similar urinary and bowel patient-reported outcomes over two years vs conventional radiotherapy. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… @AmarUKishan
-
JAMA Oncology
@JAMAOnc
Viewpoint: The growing use of immune checkpoint inhibitors in cancer treatment brings significant therapeutic benefits but also long-term immune-related adverse effects. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Viewpoint: Insights from treating chronic myeloid leukemia with tyrosine kinase inhibitors may inform EGFR-mutant lung adenocarcinoma therapy. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
This cohort study demonstrates an association between Erdheim-Chester and second cancer, and the risk of cancer was increased compared to the general population. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Viewpoint: Clinicians need improved guidelines to effectively integrate and sequence new biomarkers in clinical practice, ensuring their judicious use and optimizing patient care. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Viewpoint: A tailored, tiered approach to cancer center accreditation could increase hospital participation by addressing existing barriers and aligning costs with hospital capabilities.
jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… @alison_baskin -
JAMA Oncology
@JAMAOnc
Prophylactic radiation therapy to the contralateral breast in BRCA1/2 mutation carriers with early breast cancer significantly the onset of contralateral breast cancer compared to surveillance alone. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Combining immune checkpoint inhibitors with chemotherapy in the first line of treatment for older adults with non–small cell lung cancer can delay mortality but increases the risk of severe adverse events. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… @josephcmurray
-
JAMA Oncology
@JAMAOnc
🧵 Urinary catheters are widely used for bladder drainage but pose risks like infection, necessitating proper management.
This @JAMASurgery review summarizes types, insertion and removal techniques, complications, and strategies to reduce risks.
➡️ jamanetwork.com/journals/jamasurgery/fullarticle/10.1001/…
JAMA Oncology
@JAMAOnc
From @JAMASurgery: Catheter-associated complications, including infections, encrustation, discomfort, and urethral erosion, can be minimized by using catheters only when necessary and removing them promptly to prevent long-term issues.
➡️ jamanetwork.com/journals/jamasurgery/fullarticle/10.1001/…
JAMA Oncology
@JAMAOnc
About 100 million urinary catheters are used globally every year.
🎧 Listen to authors Anne Cameron and Glenn Werneburg of @UMich discuss best practices related to catheter management with @JAMASurgery Web Editor Amalia Cochran.
➡️ edhub.ama-assn.org/jn-learning/audio-player/18964050?link… -
JAMA Oncology
@JAMAOnc
From @JAMASurgery: Tumor-bed biopsy combined with imaging criteria does not support omitting surgery for patients with breast cancer after neoadjuvant chemotherapy, except potentially for ERBB2-positive breast cancer. jamanetwork.com/journals/jamasurgery/fullarticle/10.1001/…
-
JAMA Oncology
@JAMAOnc
Intensifying hormone treatment at the start of androgen deprivation therapy for prostate cancer increases the prevalence of androgen receptor gene alterations, which are associated with higher resistance and mortality. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… @AshwinUrol Mattsydes @FrancescaBZNY
-
JAMA Oncology
@JAMAOnc
Most viewed this week from @JAMAOnc:
Prophylactic IV magnesium administration was associated with a lower risk of cisplatin-associated acute kidney injury (CP-AKI) in patients with cancer undergoing cisplatin chemotherapy.
jamanetwork.com/journals/jamaoncology/fullarticle/2833151… -
JAMA Oncology
@JAMAOnc
In this nonrandomized clinical trial, a simplified treatment algorithm and expert support system reduced early death rates in acute promyelocytic leukemia patients from 30% to below 15%. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… @fischmd
-
JAMA Oncology
@JAMAOnc
This study found low resumption of endocrine therapy and imaging post-pregnancy in breast cancer patients, with a 19% incidence of subsequent events over 10 years. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Most viewed this week from @JAMAInternalMed:
Approximately 103,000 future cancers are projected to result from the 93 million CT examinations performed in the US in 2023, according to this study.
jamanetwork.com/journals/jamainternalmedicine/fullarticle… -
JAMA Oncology
@JAMAOnc
Many childhood cancer survivors with severe sensorineural hearing loss (SNHL) due to treatments like platinum chemotherapy and radiotherapy are now eligible for cochlear implant candidacy evaluations. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Most viewed this week from @JAMAOnc:
Prophylactic IV magnesium administration was associated with a lower risk of cisplatin-associated acute kidney injury (CP-AKI) in patients with cancer undergoing cisplatin chemotherapy.
jamanetwork.com/journals/jamaoncology/fullarticle/2833151… -
JAMA Oncology
@JAMAOnc
Review: Research advancements in acute lymphoblastic leukemia (ALL) have led to improved outcomes through the use of targeted therapies and immunotherapies, reducing the reliance on prolonged chemotherapy.
jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… -
JAMA Oncology
@JAMAOnc
Most viewed in the last 7 days from @JAMAOnc:
Cooling and compression were highly effective and significantly reduced the risk of high-grade chemotherapy-induced peripheral neuropathy.
jamanetwork.com/journals/jamaoncology/fullarticle/2830876… -
JAMA Oncology
@JAMAOnc
Cell-free DNA (cfDNA) testing could improve colorectal cancer detection and reduce mortality in Canada, but it requires higher participation rates to be effective compared to current screening methods. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… @jonathanloree
-
JAMA Oncology
@JAMAOnc
This narrative review explores how the identification of measurable residual disease through methods of detecting circulating tumor DNA contributes to outcomes for B-cell lymphomas. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
"If funding is diminished, it will be catastrophic to millions of patients and families who will experience the devastation of cancer in the coming years." Richard J Boxer discusses the effect of decreased funding for cancer research in the US. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Both hand cooling and compression were effective in preventing sensory chemotherapy-induced peripheral neuropathy during taxane-based chemotherapy. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… @mbreckwoldt
-
JAMA Oncology
@JAMAOnc
From @JAMA_current: The SPIRIT 2025 statement updates the guidelines for randomized trial protocols to enhance their completeness, transparency, and consistency, benefiting stakeholders involved in clinical research.
jamanetwork.com/journals/jama/fullarticle/10.1001/jama.20… -
JAMA Oncology
@JAMAOnc
Prophylactic IV magnesium administration was associated with a lower risk of cisplatin-associated acute kidney injury (CP-AKI) in patients with cancer undergoing cisplatin chemotherapy.
jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… -
JAMA Oncology
@JAMAOnc
Among two US prostate cancer registries, the proportion of patients undergoing prostatectomy for indolent cancer dropped over five-fold from 2010 to 2024.
jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… -
JAMA Oncology
@JAMAOnc
Viewpoint: The rise of social media and #ai in oncology has transformed scientific communication but also fuels bias, misinterpretation, and financial conflicts of interest.
jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… @oncoblogger -
JAMA Oncology
@JAMAOnc
This year, JAMA Oncology celebrates 10 years of publication. Editor in Chief @DrNDisis reflects on some of the most notable articles from the past decade and what is to come for the journal.
jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… -
JAMA Oncology
@JAMAOnc
Prophylactic IV magnesium administration was associated with a lower risk of cisplatin-associated acute kidney injury (CP-AKI) in patients with cancer undergoing cisplatin chemotherapy.
jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… -
JAMA Oncology
@JAMAOnc
Middle East and North African countries are underrepresented in oncology clinical trials, with higher participation in observational, late-phase, and industry-funded trials, and greater representation in countries with higher GDP.
jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… -
JAMA Oncology
@JAMAOnc
Most viewed in the last 7 days from @JAMAOnc:
Cooling and compression were highly effective and significantly reduced the risk of high-grade chemotherapy-induced peripheral neuropathy.
jamanetwork.com/journals/jamaoncology/fullarticle/2830876… -
JAMA Oncology
@JAMAOnc
AI and natural language processing (NLP) can effectively analyze large datasets of patient messages to generate meaningful and novel research topics in cancer care.
jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… @caswell_jin -
JAMA Oncology
@JAMAOnc
Listen to an interview with Shruti Gupta, MD, MPH, author of "Intravenous Magnesium and Cisplatin-Associated Acute Kidney Injury" hosted by @VivekSubbiah.
edhub.ama-assn.org/jn-learning/audio-player/18968105?link… -
JAMA Oncology
@JAMAOnc
Prophylactic IV magnesium administration was associated with a lower risk of cisplatin-associated acute kidney injury (CP-AKI) in patients with cancer undergoing cisplatin chemotherapy. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
This phase 1/2 nonrandomized clinical trial found the combination of PDS0101, PDS01ADC, and BA has an acceptable safety profile and showed promising clinical activity and OS outcomes in patients with advanced HPV-16–positive cancers. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… @chfloudas
-
JAMA Oncology
@JAMAOnc
Higher tumor-infiltrating lymphocytes (TILs) were strongly associated with improved overall survival in patients with ERBB2-positive early breast cancer. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… @vitti10
-
JAMA Oncology
@JAMAOnc
The PEACOCC trial showed clinical benefit with pembrolizumab in patients with previously treated advanced clear cell gynae cancer, of whom all except 1 had mismatch repair-proficient disease. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Viewpoint: Effective cancer control must include integrated strategies like updated warning labels and public education to address the cancer risk associated with alcohol consumption. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Although broad genomic profiling use in newly diagnosed metastatic cancer patients increased from 2020 to 2022, it remained below 50% overall. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… @cpgYale
-
JAMA Oncology
@JAMAOnc
Combining dasatinib with CAR T-cell therapy in newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia patients resulted in high rates of complete molecular remission.
jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… -
JAMA Oncology
@JAMAOnc
Adding atezolizumab to trastuzumab and XELOX chemotherapy increased the pathological complete response rate in patients with locally advanced ERBB2-positive gastric or gastroesophageal junction cancer.
jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… -
JAMA Oncology reposted
JAMA
@JAMA_current
Authors, editors, reviewers, and other potential users should use CONSORT 2025 when writing and evaluating manuscripts of randomized trials to ensure that trial reports are clear and transparent.
Learn more in this Special Communication. jamanetwork.com/journals/jama/fullarticle/10.1001/jama.20… -
JAMA Oncology
@JAMAOnc
Adjuvant (m)FOLFIRINOX and other multiagent chemotherapy regimens following resection of localized pancreatic adenocarcinoma after preoperative (m)FOLFIRINOX are associated with improved overall survival. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Shared care with local oncologists has the potential to become a routine model for follow-up care after allogeneic hematopoietic cell transplantation. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Most viewed in the last 7 days from @JAMAOnc:
For select breast cancer patients with complete response to neoadjuvant systemic therapy, radiotherapy alone without breast surgery may be feasible, as no tumor recurrences were observed at 5-year follow-up.
jamanetwork.com/journals/jamaoncology/fullarticle/2832067… -
JAMA Oncology
@JAMAOnc
Editorial: Children and young adults with low-risk relapsed Hodgkin lymphoma can achieve durable remission without high-dose chemotherapy and autologous stem cell transplant.
jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… -
JAMA Oncology
@JAMAOnc
Fludeoxyglucose-18-PET response-guided salvage in relapsed classic Hodgkin lymphoma may identify patients in whom transplant-free salvage achieves excellent outcomes.
jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… -
JAMA Oncology
@JAMAOnc
Transplant-free treatment approach using nivolumab plus BV and ISRT consolidation yielded high complete metabolic response and event-free survival rates in children, adolescents, and young adults with low-risk relapsed classic Hodgkin lymphoma.
jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… -
JAMA Oncology
@JAMAOnc
Viewpoint: The 21st Century Cures Act, which mandates real-time patient access to health data, aims to empower patients but has led to confusion, anxiety, and increased administrative burdens for clinicians.
jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… -
JAMA Oncology
@JAMAOnc
Most viewed in the last 7 days from @JAMAOnc:
For select breast cancer patients with complete response to neoadjuvant systemic therapy, radiotherapy alone without breast surgery may be feasible, as no tumor recurrences were observed at 5-year follow-up.
jamanetwork.com/journals/jamaoncology/fullarticle/2832067… -
JAMA Oncology
@JAMAOnc
The growing cancer burden may be met by efforts to strengthen the clinical workforce, improve gender equity, increase healthcare resource allocation, and promote universal healthcare coverage.
jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… @EChrisDee @erin_feliciano @iyengarpuneeth -
JAMA Oncology
@JAMAOnc
Ablative radiation therapy effectively controlled tumors and provided favorable 2-year survival rates in patients with resectable pancreatic cancer who could not undergo surgery.
jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… @EileenMOReilly @JohnCuaron -
JAMA Oncology
@JAMAOnc
The intracranial response rate of ipilimumab-nivolumab in patients with progressive melanoma brain metastases after prior anti-PD-1 therapy was 11%. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Integrating molecular biomarkers into radiotherapy could revolutionize treatment strategies for breast cancer patients, improving patient outcomes and quality of life. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Most viewed in the last 7 days from @JAMAOnc:
For select breast cancer patients with complete response to neoadjuvant systemic therapy, radiotherapy alone without breast surgery may be feasible, as no tumor recurrences were observed at 5-year follow-up.
jamanetwork.com/journals/jamaoncology/fullarticle/2832067… -
JAMA Oncology
@JAMAOnc
The incidence of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in the US has increased over the past two decades, particularly in the appendix, pancreas, and small intestine. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
The management of brain metastases in EGFR-variant and ALK-positive NSCLC patients remains uncertain, with evidence suggesting that upfront stereotactic radiosurgery (SRS) offers better local control and delays CNS progression. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
The use of certain oncology medications decreased after negative confirmatory trials and FDA withdrawal of accelerated approval indications. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Most viewed in the last 7 days from @JAMAOnc:
For select breast cancer patients with complete response to neoadjuvant systemic therapy, radiotherapy alone without breast surgery may be feasible, as no tumor recurrences were observed at 5-year follow-up.
jamanetwork.com/journals/jamaoncology/fullarticle/2832067… -
JAMA Oncology
@JAMAOnc
Viewpoint: Cabozantinib capsules are more cost-effective than tablets for treating various cancers, and adopting capsule-based dosing strategies could reduce costs while maintaining efficacy. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Despite the value of genomic assays in personalizing breast cancer treatment, this review found that they do not fully address racial and ethnic disparities in outcomes. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
From @JAMA_current: Listen to a discussion of "Preventive Health Care Among Adults Eligible for #lungcancer Screening." Hosted on @AMAEdHub.
edhub.ama-assn.org/jn-learning/audio-player/10.1001/jama.… -
JAMA Oncology
@JAMAOnc
From @JAMA_current: Screening for #breastcancer and #colorectalcancer among individuals eligible for lung cancer screening was nearly 4-fold higher than rates of screening for #lungcancer. jamanetwork.com/journals/jama/fullarticle/10.1001/jama.20…
-
JAMA Oncology
@JAMAOnc
This cohort study suggests that chromosomal alterations should be included in the WHO grading criteria for meningiomas, as they are associated with worse outcomes and can refine the current classification system. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
For women with low-risk ductal carcinoma in situ, health-related quality of life, anxiety, depression, and symptoms were similar whether they underwent surgery or chose active monitoring over a two-year follow-up period. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
The urinary DNA methylation test demonstrated 89% sensitivity for detecting high-grade or invasive bladder cancer in individuals with hematuria, outperforming the NMP22 test and urine cytology test with high specificity. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Intratumoral immunotherapy with pembrolizumab and mRNA-2752 appeared safe and may effectively induce regression in high-risk ductal carcinoma in situ (DCIS). jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Viewpoint provides an overview of principal illness navigation codes as well as promises and pitfalls. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Most viewed in the last 7 days from @JAMAOnc:
Survivors of childhood cancer undergo considerable accelerated aging in terms of early onset and excess risk of chronic health conditions.
jamanetwork.com/journals/jamaoncology/fullarticle/2831585… -
JAMA Oncology
@JAMAOnc
Postdiagnosis weight gain was associated with an increased risk of HF after breast cancer development, with risk escalating alongside greater weight gain. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
A study of 1.6 million US cancer patients in 2023 found 47.3% had a smoking history, with 14.7% currently smoking at diagnosis. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Most viewed in the last 7 days from @JAMAOnc:
Survivors of childhood cancer undergo considerable accelerated aging in terms of early onset and excess risk of chronic health conditions.
jamanetwork.com/journals/jamaoncology/fullarticle/2831585… -
JAMA Oncology
@JAMAOnc
This review evaluates different strategies for treating patients with advanced kidney cancer previously exposed to immunotherapy. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Are you on #whatsapp? So are we!
Follow the JAMA Network on WhatsApp channels to share the latest science and medical news from our Network with your network. www.whatsapp.com/channel/0029VamN8TzHrDZpOBe7FT3g?linkId=…
#sso2025 -
JAMA Oncology
@JAMAOnc
For select breast cancer patients with complete response to neoadjuvant systemic therapy, radiotherapy alone without breast surgery may be feasible, as no tumor recurrences were observed at 5-year follow-up. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… @HenryKuerer HelenMJohnsonMD @SFShaitelmanMD
-
JAMA Oncology
@JAMAOnc
Interval breast cancer (IntCa) rates remain high despite mammographic screening, highlighting the need for personalized screening based on risk factors like high breast density, hormone replacement therapy, and family history. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Routine advanced multidimensional molecular profiling is now required to provide optimal standard of care for patients with CNS tumors. This Review explains the rationale for multidimensional molecular diagnostics for CNS tumors. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
From @JAMADerm: RCT: Adding 3D total-body photography and sequential digital dermoscopy imaging to usual care for high-risk melanoma patients increased the number of skin excisions and biopsies. jamanetwork.com/journals/jamadermatology/fullarticle/10.1…
-
JAMA Oncology
@JAMAOnc
Beginning in 2019, fewer patients of inferred African ancestry were found to be eligible for treatment with FDA-approved precision oncology drugs compared with individuals with other inferred genetic ancestries. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
In this nonrandomized clinical trial of patients with early-stage favorable Hodgkin lymphoma treated with minimal up-front conventional chemotherapy, low-risk relapses were salvaged using conventional chemotherapy and involved-field radiotherapy. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Viewpoint outlines the importance of and known barriers to making patient-reported outcome (PRO) collection the standard of care in oncology. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Most viewed in the last 7 days from @JAMAOnc:
Cooling and compression were highly effective and significantly reduced the risk of high-grade chemotherapy-induced peripheral neuropathy.
jamanetwork.com/journals/jamaoncology/fullarticle/2830876… -
JAMA Oncology
@JAMAOnc
A 70-year-old man with a history of hypertension and chronic migraine presented with 10 months of progressive generalized muscle weakness and stiffness. Take the Clinical Challenge. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Viewpoint: Health care can improve safety and efficiency by adopting strategies from automobile safety, while balancing physician autonomy and standardization. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
In this Editorial JAMA Oncology Editor in Chief Mary L. (Nora) Disis discusses the journals impactful publications in 2024, while thanking contributors and highlighting the journal's high readership and rigorous review process. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Most viewed in the last 7 days from @JAMAOnc:
Cooling and compression were highly effective and significantly reduced the risk of high-grade chemotherapy-induced peripheral neuropathy.
jamanetwork.com/journals/jamaoncology/fullarticle/2830876… -
JAMA Oncology
@JAMAOnc
The 2021 USPSTF guidelines on lung cancer screening were associated with increased LCS uptake overall, even as cancer screenings declined during the COVID-19 pandemic. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Listen to an interview with Jennifer M. Yeh, PhD, and Lisa R. Diller, MD, authors of "Accelerated Aging in Survivors of Childhood Cancer—Early Onset and Excess Risk of Chronic Conditions" hosted by @VivekSubbiah, MD. edhub.ama-assn.org/jn-learning/audio-player/18958925?link…
-
JAMA Oncology
@JAMAOnc
Survivors of childhood cancer undergo considerable accelerated aging in terms of early onset and excess risk of chronic health conditions. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology reposted
AMA Ed Hub™
@AMAEdHub
A 36-year-old man presented with 10 weeks of recurrent fevers, malaise, night sweats, 30-lb unintentional weight loss and dyspnea. Imaging was notable for hepatosplenomegaly and a likely liver hemangioma. What is your diagnosis? @JAMAOnc amaedhub.org/4iH7L9O
-
JAMA Oncology reposted
University of Chicago Hematology/Oncology
@UChicagoHemOnc
A great new article out & advocacy from Dr. Ratain in @JAMAOnc about sotorasib for non-small cell lung cancer. Full piece at jamanetwork.com/journals/jamaoncology/article-abstract/28…
#cancercare #canceradvocacy -
JAMA Oncology
@JAMAOnc
Viewpoint: The FDA approved sotorasib for non-small cell lung cancer with the KRASG12C mutation under the accelerated approval program in 2021, but concerns remain about the consistency of confirmatory trials and appropriate dosing. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Adding chemotherapy to radiotherapy was not associated with improved overall survival for patients with intermediate-risk cervical cancer. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… @nagustiga
-
JAMA Oncology
@JAMAOnc
PSA level should be assessed for at least 3 months after radical prostatectomy to minimize overtreatment, and a higher persistent PSA level was associated with a worse prognosis. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Viewpoint: A value proposition in oncology emphasizes a clinician’s commitment to partner with patients to improve outcomes through individualized communication and shared decision-making. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
The US government contributed at least $74 million to the discovery and development of enzalutamide at its earliest stages, when the risk of failure was the highest. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
From @JAMASurgery: Fluorescence-guided lymphadenectomy may serve as an effective adjunct in minimally invasive surgery for complex gastric cancer. jamanetwork.com/journals/jamasurgery/fullarticle/10.1001/…
-
JAMA Oncology
@JAMAOnc
Chimeric antigen receptor–T-cell (CAR-T) therapy has revolutionized the treatment of hematologic cancers. This review discusses the pathobiology, epidemiology, and mitigation strategies for second primary cancers (SPCs) following therapy. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… @ShyamPatelMDPhD
-
JAMA Oncology
@JAMAOnc
Cancer prevention and screening activities were the main contributors to reductions in mortality due to the most common cancers in the US over the past 45 years. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… @CenterTobacco
-
JAMA Oncology
@JAMAOnc
From @JAMAOto: Marital status and emotional concerns are associated with clinically meaningful distress in patients with head and neck cancer. jamanetwork.com/journals/jamaotolaryngology/fullarticle/1…
-
JAMA Oncology
@JAMAOnc
In prostate cancer patients on active surveillance, high polygenic risk score was associated with risk of upgrading as well as higher prostate-specific antigen density and tumor multifocality. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Cancer prevention and screening activities were the main contributors to reductions in mortality due to the most common cancers in the US over the past 45 years. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… @CenterTobacco
-
JAMA Oncology
@JAMAOnc
Most viewed in the last 7 days from @JAMAOnc:
Viewpoint: The growing use of immune checkpoint inhibitors in cancer treatment brings significant therapeutic benefits but also long-term immune-related adverse effects.
jamanetwork.com/journals/jamaoncology/fullarticle/2830627… -
JAMA Oncology
@JAMAOnc
Despite the effectiveness of CAR-T therapy for various blood cancers, its adoption is limited in the US due to infrastructure challenges and restrictive insurance policies. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… @samyuktaMD
-
JAMA Oncology
@JAMAOnc
Most viewed in the last 7 days from @JAMAOnc:
Viewpoint: The growing use of immune checkpoint inhibitors in cancer treatment brings significant therapeutic benefits but also long-term immune-related adverse effects.
jamanetwork.com/journals/jamaoncology/fullarticle/2830627… -
JAMA Oncology
@JAMAOnc
Both hand cooling and compression were effective in preventing sensory chemotherapy-induced peripheral neuropathy during taxane-based chemotherapy. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… @mbreckwoldt
-
JAMA Oncology
@JAMAOnc
Most viewed in the last 7 days from @JAMAOnc:
This study found the combination of PDS0101, PDS01ADC, and BA has an acceptable safety profile and showed promising clinical activity and OS outcomes in patients with advanced HPV-16–positive cancers.
jamanetwork.com/journals/jamaoncology/fullarticle/2830546… -
JAMA Oncology
@JAMAOnc
Neoadjuvant nivolumab + chemotherapy followed by response-stratified chemoradiation in stage IVa/b nonvirally mediated head and neck cancer demonstrated favorable survival and less toxic effects among responders receiving response-adapted chemoradiation. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
A modified classification of progressive disease based on PD patterns in patients treated with immune checkpoint inhibitors showed an association with postprogression survival (PPOS) across various solid tumor. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Men with clinically suspected prostate cancer and negative MRI results can safely avoid biopsies with appropriate monitoring, validating the high negative predictive value of prebiopsy MRI in community healthcare settings. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
In patients with locally advanced hepatocellular carcinoma, stereotactic body radiation therapy (SBRT) combined with sorafenib improved progression-free survival and showed a clinically important improvement in overall survival compared to sorafenib alone. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Viewpoint: The growing use of immune checkpoint inhibitors in cancer treatment brings significant therapeutic benefits but also long-term immune-related adverse effects. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
This cohort study demonstrates an association between Erdheim-Chester and second cancer, and the risk of cancer was increased compared to the general population. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Most viewed in the last 7 days from @JAMAOnc:
This study found the combination of PDS0101, PDS01ADC, and BA has an acceptable safety profile and showed promising clinical activity and OS outcomes in patients with advanced HPV-16–positive cancers.
jamanetwork.com/journals/jamaoncology/fullarticle/2830546… -
JAMA Oncology
@JAMAOnc
RCT: Intensifying hormone treatment at the start of androgen deprivation therapy for prostate cancer increases the prevalence of androgen receptor gene alterations, which are associated with higher resistance and mortality. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Listen to an interview with Anand P. Jillella author of "Academic-Community Partnership and Deaths in Promyelocytic Leukemia: The Nonrandomized ECOG-ACRIN EA9131 Trial" hosted by @VivekSubbiah.
edhub.ama-assn.org/jn-learning/audio-player/18953965?link… -
JAMA Oncology
@JAMAOnc
In this nonrandomized clinical trial, a simplified treatment algorithm and expert support system reduced early death rates in acute promyelocytic leukemia patients from 30% to below 15%. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… @fischmd
-
JAMA Oncology
@JAMAOnc
A cord D0.1cc constraint of 19.1 Gy and a Dmax constraint of 20.8 Gy correspond with a 1.0% risk of grade 3 to 4 radiation myelitis 2 years after spine SBRT for spinal metastases. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Intratumoral delivery of dendritic cells combined with anti-HER2 antibodies is safe and effective in altering the tumor microenvironment and inducing dramatic tumor regression prior to chemotherapy in early-stage HER2-positive breast cancer. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Most viewed in the last 7 days from @JAMAOnc:
Tumor-infiltrating lymphocytes can serve as a biomarker to identify patients with ERBB2-positive early breast cancer who may safely undergo de-escalated adjuvant therapy without compromising long-term SO.
jamanetwork.com/journals/jamaoncology/fullarticle/2830196… -
JAMA Oncology
@JAMAOnc
A deep learning #ai model showed improved accuracy over existing biomarkers in predicting immune checkpoint inhibitor treatment response in advanced non-small cell lung cancer patients. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Viewpoint: Insights from treating chronic myeloid leukemia with tyrosine kinase inhibitors may inform EGFR-mutant lung adenocarcinoma therapy. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Most viewed in the last 7 days from @JAMAOnc:
Tumor-infiltrating lymphocytes can serve as a biomarker to identify patients with ERBB2-positive early breast cancer who may safely undergo de-escalated adjuvant therapy without compromising long-term SO.
jamanetwork.com/journals/jamaoncology/fullarticle/2830196… -
JAMA Oncology
@JAMAOnc
This narrative review outlines the historical evolution of the COG Long-Term Follow-Up Guidelines for Survivors of Childhood, Adolescent, and Young Adult Cancers, current methods guiding their development, and key recommendations from version 6.0. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
This phase 1/2 nonrandomized clinical trial found the combination of PDS0101, PDS01ADC, and BA has an acceptable safety profile and showed promising clinical activity and OS outcomes in patients with advanced HPV-16–positive cancers. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Higher tumor-infiltrating lymphocytes (TILs) were strongly associated with improved overall survival in patients with ERBB2-positive early breast cancer. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Most viewed in the last 7 days from @JAMAOnc:
The PEACOCC trial showed clinical benefit with pembrolizumab in patients with previously treated advanced clear cell gynae cancer, of whom all except 1 had mismatch repair-proficient disease.
jamanetwork.com/journals/jamaoncology/fullarticle/2829929… -
JAMA Oncology
@JAMAOnc
Higher tumor-infiltrating lymphocytes (TILs) were strongly associated with improved overall survival in patients with ERBB2-positive early breast cancer. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Most viewed in the last 7 days from @JAMAOnc:
The PEACOCC trial showed clinical benefit with pembrolizumab in patients with previously treated advanced clear cell gynae cancer, of whom all except 1 had mismatch repair-proficient disease.
jamanetwork.com/journals/jamaoncology/fullarticle/2829929… -
JAMA Oncology
@JAMAOnc
This study found low resumption of endocrine therapy and imaging post-pregnancy in breast cancer patients, with a 19% incidence of subsequent events over 10 years. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Higher tumor-infiltrating lymphocytes (TILs) were strongly associated with improved overall survival in patients with ERBB2-positive early breast cancer. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
The incidence of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in the US has increased over the past two decades, particularly in the appendix, pancreas, and small intestine. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Integrating molecular biomarkers into radiotherapy could revolutionize treatment strategies for breast cancer patients, improving patient outcomes and quality of life. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Intratumoral immunotherapy with pembrolizumab and mRNA-2752 appeared safe and may effectively induce regression in high-risk ductal carcinoma in situ (DCIS). jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Most viewed in the last 7 days from @JAMAOnc:
Does a noninvasive urinary DNA methylation test have high accuracy for the diagnosis of bladder cancer?
jamanetwork.com/journals/jamaoncology/fullarticle/2829522… -
JAMA Oncology
@JAMAOnc
Viewpoint describes the optimal approach to therapy selection for patients with cancer using biomarkers. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Most viewed in the last 7 days from @JAMAOnc:
Does a noninvasive urinary DNA methylation test have high accuracy for the diagnosis of bladder cancer?
jamanetwork.com/journals/jamaoncology/fullarticle/2829522… -
JAMA Oncology
@JAMAOnc
This narrative review explores how the identification of measurable residual disease through methods of detecting circulating tumor DNA contributes to outcomes for B-cell lymphomas. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
From @JAMASurgery: Sassun-Mayo N/tumor, lymph node, and metastasis staging provided superior overall survival stratification vs the current @AJCCancer staging, suggesting that their implementation could improve prognostication in colon cancer. jamanetwork.com/journals/jamasurgery/fullarticle/10.1001/…
-
JAMA Oncology
@JAMAOnc
The PEACOCC trial showed clinical benefit with pembrolizumab in patients with previously treated advanced clear cell gynae cancer, of whom all except 1 had mismatch repair-proficient disease. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Viewpoint: Stephanie Wang, @fumikochino, and @EChrisDee discuss factors contributing to financial toxicity among Asian American cancer survivors, including socioeconomic disparities, family-centric care approaches, and cultural coping mechanisms. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Clinical dataset demonstrates that inferring human leukocyte antigen (HLA) genotypes is highly concordant to dedicated HLA testing. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
An analysis of cancer drugs granted accelerated approval in the US revealed that two-thirds were also approved in the EU, and nearly half of those lack a verified clinical benefit in terms of overall survival or quality of life. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Most viewed in the last 7 days from @JAMAOnc:
(m)FOLFIRINOX and other multiagent chemotherapy regimens were associated with improved OS following resection of localized pancreatic adenocarcinoma after preoperative (m)FOLFIRINOX.
jamanetwork.com/journals/jamaoncology/fullarticle/2829411… -
JAMA Oncology
@JAMAOnc
Listen to an interview with Michael A. Postow, MD, author of "Intracranial Outcomes of Ipilimumab and Nivolumab in Melanoma Brain Metastases After Progression on Anti–PD-1 Therapy" hosted by @VivekSubbiah.
edhub.ama-assn.org/jn-learning/audio-player/18946448?link… -
JAMA Oncology
@JAMAOnc
Most viewed in the last 7 days from @JAMAOnc:
(m)FOLFIRINOX and other multiagent chemotherapy regimens were associated with improved OS following resection of localized pancreatic adenocarcinoma after preoperative (m)FOLFIRINOX.
jamanetwork.com/journals/jamaoncology/fullarticle/2829411… -
JAMA Oncology reposted
NM Urology
@NM_Urology
A study by @NorthwesternMed investigators, senior authored by @EdwardSchaeffer, MD, PhD, published in @JAMAOnc suggests that using an alternative approach, a percutaneous, transperineal prostate biopsy, is as effective at detecting cancer as the transrectal approach, but without the risk of infection or need for prophylactic antibiotics.
news.feinberg.northwestern.edu/2024/09/30/study-advocates… -
JAMA Oncology reposted
Wyn Dobbs
@wyndobbs
Excited to share our @JAMAOnc paper on CMS’s new PIN codes for illness navigation! These codes aim to improve access to lifesaving care for patients with complex conditions. Our piece examines the promises and pitfalls ahead. @SamyuktaMD @QasimHussainiMD
jamanetwork.com/journals/jamaoncology/article-abstract/28… -
JAMA Oncology
@JAMAOnc
The intracranial response rate of ipilimumab-nivolumab in patients with progressive melanoma brain metastases after prior anti-PD-1 therapy was 11%. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… @jsmithymd
-
JAMA Oncology
@JAMAOnc
From @JAMA_current: "So what does this mean for clinical practice? IMpassion030 may have been our last large-scale trial of adjuvant immune checkpoint inhibitor in TNBC."
Read the Editorial.
jamanetwork.com/journals/jama/fullarticle/10.1001/jama.20… -
JAMA Oncology
@JAMAOnc
From @JAMA_current: The addition of the immune therapy drug atezolizumab to postoperative chemotherapy did not improve invasive disease-free survival among patients with high-risk early-stage triple-negative breast cancer.
jamanetwork.com/journals/jama/fullarticle/10.1001/jama.20… -
JAMA Oncology
@JAMAOnc
The urinary DNA methylation test demonstrated 89% sensitivity for detecting high-grade or invasive bladder cancer in individuals with hematuria, outperforming the NMP22 test and urine cytology test with high specificity. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
From @JAMAInternalMed: Your loved one has cancer—what does this mean for you? This JAMA Internal Medicine Patient Page describes the role and challenges of caring for a loved one with cancer. @WarrierMD jamanetwork.com/journals/jamainternalmedicine/fullarticle…
-
JAMA Oncology
@JAMAOnc
This Review discusses approaches to the management of central nervous system metastases for non–small cell lung cancer with the incorporation of molecular and genomic markers in the treatment paradigms. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
In this Special Communication, three strategies are proposed to make cancer drugs more accessible and affordable in low- and middle-income countries. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Individuals with a negative colonoscopy screening may not need a repeat exam for at least 20 years, according to a study of ~200,000 participants followed for up to 32 years. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Most viewed in the last 7 days from @JAMAOnc:
Intratumoral immunotherapy with pembrolizumab and mRNA-2752 appeared safe and showed promising efficacy for high-risk ductal carcinoma in situ (DCIS).
jamanetwork.com/journals/jamaoncology/fullarticle/2829035… -
JAMA Oncology
@JAMAOnc
Pediatric colorectal adenocarcinomas often present in advanced stages with poor survival outcomes, particularly in cases involving signet ring cell carcinoma and rectal cancer. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Most viewed in the last 7 days from @JAMAOnc:
Intratumoral immunotherapy with pembrolizumab and mRNA-2752 appeared safe and showed promising efficacy for high-risk ductal carcinoma in situ (DCIS).
jamanetwork.com/journals/jamaoncology/fullarticle/2829035… -
JAMA Oncology
@JAMAOnc
Viewpoint provides an overview of principal illness navigation codes as well as promises and pitfalls.
@samyuktaMD
jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… -
JAMA Oncology
@JAMAOnc
Adjuvant (m)FOLFIRINOX and other multiagent chemotherapy regimens following resection of localized pancreatic adenocarcinoma after preoperative (m)FOLFIRINOX are associated with improved overall survival.
@TFStoop @chiaro_del
jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… -
JAMA Oncology
@JAMAOnc
CAIRO5 RCT: No overall survival benefit was found for different induction regimens in patients with initially unresectable colorectal cancer liver metastases; FOLFOX/FOLFIRI plus bevacizumab is recommended. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Olverembatinib, a third-generation BCR-ABL1 TKI, is well-tolerated and effective in treating chronic myeloid leukemia (CML) with resistance to or intolerance of previous TKIs. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
In a phase 3 trial, adding the novel PD-1 inhibitor toripalimab to standard chemotherapy improved progression-free survival and overall survival in patients with extensive-stage small cell lung cancer. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Viewpoint outlines the importance of and known barriers to making patient-reported outcome (PRO) collection the standard of care in oncology. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Most viewed in the last 7 days from @JAMAOnc:
Postdiagnosis weight gain was associated with an increased risk of heart failure after breast cancer development, with risk escalating alongside greater weight gain.
jamanetwork.com/journals/jamaoncology/fullarticle/2828795… -
JAMA Oncology
@JAMAOnc
The incidence of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in the US has increased over the past two decades, particularly in the appendix, pancreas, and small intestine. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Most viewed in the last 7 days from @JAMAOnc:
Postdiagnosis weight gain was associated with an increased risk of heart failure after breast cancer development, with risk escalating alongside greater weight gain.
jamanetwork.com/journals/jamaoncology/fullarticle/2828795… -
JAMA Oncology
@JAMAOnc
Integrating molecular biomarkers into radiotherapy could revolutionize treatment strategies for breast cancer patients, improving patient outcomes and quality of life. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Intratumoral immunotherapy with pembrolizumab and mRNA-2752 appeared safe and may effectively induce regression in high-risk ductal carcinoma in situ (DCIS). jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Most viewed in the last 7 days from @JAMAOnc:
Individuals with a negative colonoscopy screening may not need a repeat exam for at least 20 years, according to a study of ~200,000 participants followed for up to 32 years.
jamanetwork.com/journals/jamaoncology/fullarticle/2827109… -
JAMA Oncology
@JAMAOnc
This study provides a guidance document to educate clinicians and patients on biomarkers informing prognosis and treatment in unresectable or metastatic gastroenteropancreatic neuroendocrine neoplasms. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
In men diagnosed with GG1 prostate cancer undergoing active surveillance, higher adherence to American dietary guideline recommendations may be associated with a lower risk of grade reclassification. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Prostate cancer (PCa) is uncommon in transgender women and gender-affirming hormone therapy may reduce the risk of PCa but worsen the prognosis, this study found. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Fludeoxyglucose-18-PET response-guided salvage in relapsed classic Hodgkin lymphoma may identify patients in whom transplant-free salvage achieves excellent outcomes. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Transplant-free treatment approach using nivolumab plus BV and ISRT consolidation yielded high complete metabolic response and event-free survival rates in children, adolescents, and young adults with low-risk relapsed classic Hodgkin lymphoma. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Viewpoint: Health care can improve safety and efficiency by adopting strategies from automobile safety, while balancing physician autonomy and standardization. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Postdiagnosis weight gain was associated with an increased risk of HF after breast cancer development, with risk escalating alongside greater weight gain. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Most viewed in the last 7 days from @JAMAOnc:
Individuals with a negative colonoscopy screening may not need a repeat exam for at least 20 years, according to a study of ~200,000 participants followed for up to 32 years.
jamanetwork.com/journals/jamaoncology/fullarticle/2827109… -
JAMA Oncology
@JAMAOnc
Transplant-free treatment approach using nivolumab plus BV and ISRT consolidation yielded high complete metabolic response and event-free survival rates in children, adolescents, and young adults with low-risk relapsed classic Hodgkin lymphoma. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Fludeoxyglucose-18-PET response-guided salvage in relapsed classic Hodgkin lymphoma may identify patients in whom transplant-free salvage achieves excellent outcomes. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Beginning in 2019, fewer patients of inferred African ancestry were found to be eligible for treatment with FDA-approved precision oncology drugs compared with individuals with other inferred genetic ancestries. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
In this nonrandomized clinical trial of patients with early-stage favorable Hodgkin lymphoma treated with minimal up-front conventional chemotherapy, low-risk relapses were salvaged using conventional chemotherapy and involved-field radiotherapy. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Shared care with local oncologists has the potential to become a routine model for follow-up care after allogeneic hematopoietic cell transplantation. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Editorial: Children and young adults with low-risk relapsed Hodgkin lymphoma can achieve durable remission without high-dose chemotherapy and autologous stem cell transplant, using therapies like immunotherapy and radiotherapy.
jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
@rabihannaMD -
JAMA Oncology
@JAMAOnc
Transplant-free treatment approach using nivolumab plus BV and ISRT consolidation yielded high complete metabolic response and event-free survival rates in children, adolescents, and young adults with low-risk relapsed classic Hodgkin lymphoma.
jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… -
JAMA Oncology
@JAMAOnc
Fludeoxyglucose-18-PET response-guided salvage in relapsed classic Hodgkin lymphoma may identify patients in whom transplant-free salvage achieves excellent outcomes.
jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… -
JAMA Oncology
@JAMAOnc
Quitting smoking within 6 months of a cancer diagnosis improves survival outcomes, with the greatest benefits observed in those who enter cessation programs promptly. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
FUMANBA-1 trial: In patients with heavily pretreated relapsed or refractory multiple myeloma (RRMM), a single infusion of equecabtagene autoleucel (eque-cel) resulted in an overall response rate of 96%. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Mutation-matched targeted therapy plus immune checkpoint inhibitor, atezolizumab, resulted in a long median overall survival in anaplastic thyroid carcinoma. @DrMCabanillas @MDAndersonNews jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Viewpoint outlines the missions of academic cancer centers and how they are being affected by the oncology industrial complex along with challenges and suggestions for an aligned way forward. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Dual immune checkpoint inhibition with nivolumab and ipilimumab showed a response rate of only 9.4% in radioiodine refractory differentiated thyroid cancer and did not meet the primary end point of trial. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
From @JAMAOto: Patients with recurrent oropharyngeal cancer (rOPC) and their caregivers prioritize survival during initial treatment decisions, but their focus shifts towards quality of life as treatment progresses and prognosis changes. jamanetwork.com/journals/jamaotolaryngology/fullarticle/1…
-
JAMA Oncology
@JAMAOnc
In randomized clinical trials of cancer screening, incidence of late-stage cancer may be a suitable alternative end point to cancer-specific mortality for some cancer types but is not suitable for others, finds meta-analysis of 41 RCTs. jamanetwork.com/journals/jama/fullarticle/10.1001/jama.20… #aacr24
-
JAMA Oncology
@JAMAOnc
Results of this trial suggest that, for women without findings of pathogenic variants, not mandating genetic counseling for cancer risk testing did not increase posttest distress, providing an alternative model for care delivery for a low-risk population. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
JAMA Oncology Web Editor @JackWestMD and Sean P. Pitroda, MD, discuss "Integrated Clinical-Molecular Classification of Colorectal Liver Metastases: A Biomarker Analysis of the Phase 3 New EPOC Randomized Clinical Trial." edhub.ama-assn.org/jn-learning/audio-player/10.1001/jamao…
-
JAMA Oncology
@JAMAOnc
This large nonrandomized clinical trial of patients with MET exon 14–skipping NSCLC supports global approvals of tepotinib, enabling clinicians to implement optimal therapeutic approaches.
#asco23
jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… -
JAMA Oncology
@JAMAOnc
Nested case-control cohort study found that the rate of change in breast density was associated with the risk of subsequent breast cancer. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… #bcsm
-
JAMA Oncology
@JAMAOnc
"Prioritizing Cancer Care in a Pandemic: Applying Lessons from Low Resource Settings" Rebecca DeBoer, Katherine Van Loon @UCSF leverage expertise from global oncology collaborations in managing #cancer in the US during #covid19 jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…
-
JAMA Oncology
@JAMAOnc
Cohort study finds #covid19 pandemic is associated with system-wide decrease in enrollment to @theNCI #clinicaltrials, especially the states most hard-hit. @SWOG @FredHutch jama.jamanetwork.com/article.aspx?doi=10.1001/jamanetwork…
-
JAMA Oncology
@JAMAOnc
Precision medicine may become a long-awaited reality to inform patient care in the frontline treatment of metastatic renal cell carcinoma jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… #gucsm jamanetwork.com/journals/jamaoncology/fullarticle/2757080…
-
JAMA Oncology
@JAMAOnc
New findings support the use of the 21-gene RS assay to guide the use of adjuvant chemotherapy in patients with hormone receptor–positive, ERBB2-negative, axillary node-negative #breastcancer jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… #esmo19
-
JAMA Oncology
@JAMAOnc
Review of data from 244,808 pts in Central Brain Tumor Registry w #glioma reveals marked differences in incidence & survival by race, w non-Hispanic whites, esp men, having highest incidence lowest survival across most histologies. Read more jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… #btsm
-
JAMA Oncology
@JAMAOnc
Visit jamanetwork.com/journals/jamaoncology/fullarticle/2578708 to review the mechanisms of viral carcinogenesis, with an emphasis on the viral evasion of the host immune system, and discuss how to harness the immune system effectively as a therapeutic tool in select #cancers. #immunoonc18
-
JAMA Oncology
@JAMAOnc
Cost-effectiveness of Ovarian Cancer Screening in the United States jamanetwork.com/journals/jamaoncology/fullarticle/2665173
-
JAMA Oncology
@JAMAOnc
Screening for #ovariancancer in US is potentially cost-effective but depends on financial thresholds for mortality reduction & cost of CA-125 risk algorithm. jamanetwork.com/journals/jamaoncology/fullarticle/10.1001… #gyncsm
-
JAMA Oncology
@JAMAOnc
Eliminate selection, immortal time bias: eliminate survival benefit of #statins in #cancer pts in SEER analysis jamanetwork.com/journals/jamaoncology/fullarticle/10.1001…


























































































































































































































































































































































































































































































































































































































































































































































